Clinical and Molecular Hepatology

"Hepatitis B Virus"

Research Letters

Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks: Kui Wang, Ruchen Zhou; Clin Mol Hepatol 2026;32(2):e211-e215.
Published online March 11, 2026; DOI: https://doi.org/10.3350/cmh.2026.0151

754 View
32 Download

Extrahepatic mortality associated with chronic liver disease with or without cirrhosis from 2014 to 2024: Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed; Clin Mol Hepatol 2026;32(2):e194-e198.
Published online February 25, 2026; DOI: https://doi.org/10.3350/cmh.2026.0225

583 View
33 Download

Editorial

From Metabolites to Chromatin: ACSS2-Driven Acetyl-CoA Fuels H3K27ac Chromatin Remodeling in HBV-Associated HCC: Hyeong-Jin Cho, Sung-Gyoo Park; Received January 23, 2026 Accepted January 24, 2026 Published online February 2, 2026; DOI: https://doi.org/10.3350/cmh.2026.0114 [Accepted]

690 View
52 Download

Correspondences

Correspondence to editorial on "New Insights into Antibody-Mediated NK Cell Immunity in Hepatitis B": Libo Tang, Yuhao Wang, Zihan Jin, Shihong Zhong, Yongyin Li; Received January 20, 2026 Accepted January 24, 2026 Published online February 2, 2026; DOI: https://doi.org/10.3350/cmh.2026.0096 [Accepted]

518 View
12 Download

Correspondence to letter regarding "From Immune Reshaping to Functional Cure: Translational Considerations for NK Cell Therapy in HBV": Zihan Jin, Libo Tang, Yuhao Wang, Shihong Zhong, Yongyin Li; Received January 20, 2026 Accepted January 24, 2026 Published online February 2, 2026; DOI: https://doi.org/10.3350/cmh.2026.0095 [Accepted]

547 View
25 Download

Review

Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease: Chieh Liu, Yi-Fen Shih, Chun-Jen Liu; Clin Mol Hepatol 2026;32(2):565-579.
Published online January 9, 2026; DOI: https://doi.org/10.3350/cmh.2025.1227

Abstract
PDF

Hepatitis B virus (HBV) remains a major cause of chronic liver diseases, especially in the Asia-Pacific region. In recent decades, coinfection with hepatitis C virus (HCV) and coexistence with metabolic dysfunction-associated steatotic liver disease (MASLD) have emerged as significant clinical concerns among HBV-infected patients. Although global HBV vaccination programs and curative therapies for HCV have led to a marked decline in HBV/HCV coinfection, MASLD is rapidly becoming the predominant comorbidity due to the global surge in metabolic risk factors. HBV/HCV coinfection typically results in more severe liver damage, with unique challenges in antiviral treatment and risk of HBV reactivation post-HCV clearance. In contrast, HBV/MASLD overlap demonstrates complex metabolic-viral interactions that may influence viral replication, hepatitis B surface antigen seroclearance, fibrosis progression, and risk of hepatocellular carcinoma. This review critically compares the epidemiology, clinical outcomes, and management strategies of HBV patients with concurrent HCV or MASLD, while addressing current research gaps and proposing directions for future investigations.

1,009 View
91 Download

Original Articles

Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1⁺KLRC2^–CD16^hi subset linked to hepatitis B virus outcomes: Libo Tang, Yuhao Wang, Zihan Jin, Yurong Gu, Zhaofeng Zeng, Linnan Song, Xuan Yi, Lingtao Zhang, Yujing Zhang, Weiying He, Liping Wang, Weixin He, Jianru Sun, Xiaoqin Lan, Xiangyong Li, Shihong Zhong, Yongyin Li; Clin Mol Hepatol 2026;32(2):683-705.
Published online December 19, 2025; DOI: https://doi.org/10.3350/cmh.2025.0842

Background/Aims
Natural killer (NK) cell function is generally considered dampened in chronic hepatitis B virus (HBV) infection; however, the NK cell pool exhibits phenotypic and functional heterogeneity, and the antibody--mediated effect of NK cells remains less characterized. This study evaluated the dynamic changes in antibody-mediated NK cell responses and the involvement of distinct NK subsets across disease stages and during antiviral treatment.
Methods
A T-cell receptor-like antibody specific for the HBV core 18–27 peptide (cTCRL-Ab) was used to determine the antibody-mediated effect of NK cells, and an array of NK cell surface markers were analyzed in cross-sectional and longitudinal cohorts of patients with chronic HBV infection. Single-cell RNA sequencing (scRNA-seq) was performed to identify the heterogeneity of NK subsets.
Results
The cTCRL-Ab enabled the detection of NK cell cytolytic activity and IFNγ production. Notably, cTCRL-Ab-mediated NK cell responses were compromised in chronically HBV-infected patients, particularly in those receiving pegylated interferon-α (Peg-IFNα), which was associated with the downregulation of CD16 expression. Correspondingly, Peg-IFNα inhibited cTCRL-Ab-mediated NK cell function by reducing CD16 expression in vitro. scRNA-seq revealed that CD16 downregulation occurred mainly within a dysfunctional CD16hi NK subset exhibiting exhaustion properties. In contrast, an activated CD16^hiNK subpopulation (CX3CR1⁺KLRC2^–CD16^hi) with high cytotoxicity was enriched in patients who experienced favorable treatment responses. Furthermore, the intrahepatic CX3CR1⁺KLRC2^–CD16^hi subset tended to exhibit functional restoration in HBsAg-loss individuals.
Conclusions
Our data contribute to the understanding of antibody-mediated responses of NK cells in chronic HBV infection, and highlight a previously unappreciated functional CX3CR1⁺KLRC2^–CD16^hiNK subset as a potential therapeutic target.

Citations

Citations to this article as recorded by

Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B
Liya Zhu, Fei Peng, Dingfang Pi, Jinzhi Lu
Frontiers in Immunology.2026;[Epub] CrossRef

1,145 View
131 Download
Crossref

Acetyl-coenzyme A synthetase 2-mediated acetyl-coenzyme A accumulation promotes mitophagy and tumor growth via increased H3K27ac in hepatitis B virus-related hepatocellular carcinoma: Shan Li, Jie Hu, Yihan Yan, Xinrui Liu, Xiao Dong, Huijun Liang, Xin Tang, Junji Tao, Rong Zhang, Yuan Hu, Ailong Huang, Kai Wang, Ni Tang; Clin Mol Hepatol 2026;32(2):661-682.
Published online December 19, 2025; DOI: https://doi.org/10.3350/cmh.2025.0754

Background/Aims
Acetyl coenzyme A (acetyl-CoA) is one of the most essential metabolites in cell metabolism but its function and concentration in hepatocellular carcinoma (HCC) remain elusive and controversial.
Methods
A comprehensive analysis of acetyl-CoA levels and acetyl-CoA synthetase 2 (ACSS2) expression across a range of samples, including patient specimens from both hepatitis B virus (HBV) positive and HBV negative HCC individuals, HBV-transgenic mouse HCC models, and multiple cell lines. Furthermore, to evaluate the functional significance of ACSS2 in HBV-related HCC, we implemented both genetic and pharmacological inhibition strategies targeting ACSS2. Molecular mechanism and mitophagy assessment were revealed by cleavage under target and tagmentation sequencing, RNA sequencing, bioinformatic analyses, transmission electron microscopy and JC-1 staining.
Results
Our study revealed a distinct metabolic signature of HBV-related HCC, marked by elevated acetyl-CoA, which was driven by ACSS2. ACSS2 was upregulated by the carbohydrate response element-binding protein in HBV-related HCC. Furthermore, ACSS2 improved tumor cell proliferation, an effect that was dependent on its enzymatic activity. Mechanistically, ACSS2-induced acetyl-CoA accumulation activated voltage-dependent anion channels 1 transcription through increased H3K27ac occupancy, which subsequently promoted mitophagy and HBV-related HCC tumorigenesis. Notably, targeting ACSS2 by depletion or inhibition with a catalytic inhibitor significantly suppressed tumor growth.
Conclusions
These findings not only illustrate the interplay between metabolic reprogramming, epigenetic modification, and tumorigenesis in the context of HBV infection, but also highlight ACSS2 as a novel metabolic vulnerability in HBV-related HCC. Therefore, targeting ACSS2 could be a novel strategy against HBV-related HCC.

2,481 View
429 Download

Review

Targeting the innate immune system in treating hepatitis B: prospects for functional cure: Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak; Clin Mol Hepatol 2026;32(1):184-199.
Published online November 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0935

Abstract
PDF

Chronic hepatitis B (CHB) infection remains a significant global public health concern. Functional cure, defined as hepatitis B surface antigen seroclearance with unquantifiable HBV DNA at 24 weeks off treatment, is a desirable endpoint in the treatment of CHB, yet challenging to achieve. Given the limitations of current therapies including nucleos(t)ide analogues and pegylated interferon alpha, novel agents targeting functional cure are emerging. As hepatitis B virus (HBV) is a non-cytolytic virus, liver damage stems from the host immune response towards HBV-infected cells. The innate immune response during the initial phase of HBV infection is crucial in establishing an adequate level of immunity against the virus. However, HBV adopts various mechanisms to evade the host’s innate immunity, partly contributing to the chronicity of infection. This article provides a comprehensive review on how the HBV life cycle interacts with the host’s innate immune system. The latest evidence of novel agents targeting the innate immunity will also be covered. Retinoic acid inducible gene I agonists, toll-like receptor agonists, and interferons are therapies that target the HBV evasion strategies against host’s innate immunity. While small interfering RNAs and antisense oligonucleotides are originally designed for antigen knockdown and reinvigoration of the adaptive immune response, they have also shown additional impacts on the innate immunity. With ongoing research and innovation in combination strategies, advancement in the management of CHB is anticipated in the future.

Citations

Citations to this article as recorded by

Current Status and Prospects of Clinical Research on Low-Level Viremia in Chronic Hepatitis B after Treatment
颜刘
Advances in Clinical Medicine.2026; 16(03): 1942. CrossRef

2,301 View
236 Download
Crossref

Correspondence

Redefining MTCT prevention strategies toward HBV elimination: Correspondence to editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”: Moran Ki, Jong-Hyun Kim; Clin Mol Hepatol 2026;32(2):e224-e226.
Published online July 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0805

2,026 View
45 Download

Research Letter

Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023: Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed; Clin Mol Hepatol 2026;32(1):e24-e28.
Published online July 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0802

Citations

Citations to this article as recorded by

Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha
Liver International.2026;[Epub] CrossRef
Improved survival and reduced alcohol‐associated hepatitis risk with renin‐angiotensin‐aldosterone system inhibitors in alcohol‐associated liver disease
Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Andrew F. Ibrahim, Primrose Tothanarungroj, Omar Al Ta'ani, Narathorn Kulthamrongsri, Kwanjit Duangsonk, Robert J. Wong, Daniel Q. Huang, Karn Wijarnpreecha, Mazen Noureddin, Suthat Liangpunsakul
Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef

3,277 View
70 Download
2 Web of Science
Crossref

Editorial

Breaking the chain of perinatal hepatitis B transmission: Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”: Shang-Chin Huang, Jia-Horng Kao; Clin Mol Hepatol 2026;32(2):946-948.
Published online July 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0801

2,028 View
21 Download

Review

Global strategies and actions to eliminate hepatitis B virus infection: Chih-Lin Lin, Jia-Horng Kao; Clin Mol Hepatol 2025;31(4):1197-1212.
Published online July 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0492

Abstract
PDF

Through the implementation of hepatitis B vaccination and effective antiviral treatment over the past four decades, the hepatitis B surface antigen (HBsAg) seroprevalence of the vaccinated generation dramatically decline. The incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) also decreases. However, the elimination of HBV is still a challenge to achieve. Novel HBV biomarkers, including quantitative HBsAg, hepatitis B virus core-related antigen and HBV RNA are promising in predicting clinical phases, risks of disease progression and HBV functional cure. Current antiviral therapies, nucleoside/nucleotide and pegylated alpha-interferon, effectively decrease HCC incidence in chronic hepatitis B (CHB) patients and minimize the recurrence of HCC in patients receiving curative therapy. Novel agents under development to achieve HBV cure include direct-acting antivirals that target various stages of the HBV lifecycle and host targeting agents that enhance HBV-specific immunity. The action plans for eliminating hepatitis B in the future are universal HBV screening, early and simplified treatment as well as precision lifelong management for CHB patients. This narrative review will summarize and discuss global strategies and initiatives aimed at eliminating HBV infection.

Citations

Citations to this article as recorded by

Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches
Prashant Tiwari, Istuti Saraswat, Jyoti Gupta
Current Microbiology.2026;[Epub] CrossRef
Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification
Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao
Hepatology Communications.2026;[Epub] CrossRef
Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications
Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou
Portal Hypertension & Cirrhosis.2026; 5(1): 65. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef

5,827 View
245 Download
3 Web of Science
Crossref

Letter to the Editor

Reconsidering the role of plasma pgRNA in NUC-treated CHB: Stratified biomarker interpretation and the limits of current assays: Letter to the editor on “Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters”: Xu Han, Jun Sun, Yinyan Li; Clin Mol Hepatol 2026;32(2):e131-e133.
Published online July 9, 2025; DOI: https://doi.org/10.3350/cmh.2025.0642

1,924 View
37 Download

Original Article

Factors associated with hepatitis B mother-to-child transmission in a national prevention program: Moran Ki, Byung-Woo Kim, Dahye Baik, Jong-Hyun Kim; Clin Mol Hepatol 2025;31(4):1298-1315.
Published online June 24, 2025; DOI: https://doi.org/10.3350/cmh.2025.0214

Background/Aims
Hepatitis B virus (HBV) mother-to-child transmission (MTCT) remains a global health concern, with over 90% of perinatal infections leading to chronic HBV. To evaluate long-term trends in MTCT rates and associated factors within Korea’s national program.
Methods
Population-based cohort study using linked data from the Perinatal Hepatitis B Prevention Program (PHBPP) and National Health Insurance Service in Korea. The study included HBsAg-positive mother-infant pairs with post-vaccination serologic results from 2002 to 2021.
Results
Among the 154,478 mother-infant pairs, the overall MTCT rate after prophylaxis was 2.3%. Antiviral use lowered MTCT rates (0.9% vs. 2.4%) particularly in HBeAg-positivity (1.0% vs. 5.9%; adjusted odds ratio [aOR] 0.21; 95% confidence interval [CI] 0.14–0.32). Lower MTCT rates were observed for cesarean section vs. vaginal delivery (1.9% vs. 2.6%; aOR 0.78; 95% CI 0.73–0.84) and breastfeeding vs. formula feeding (1.8% vs. 2.8%; aOR 0.65; 95% CI 0.56–0.76). Annual MTCT rates decreased from 3.6% (2002–2005) to 1.3% (2018–2021). Antivirals reduced MTCT rates; initiation at 14–27 weeks (0.39%), or 28–32 weeks (0.44%) vs. ≥33 weeks (1.47%); postpartum continuation (0.55%) vs. antepartum discontinuation (1.44%); use ≥61 days (0.51%) vs. 1–60 days (1.67%). Lower MTCT risk was associated with maternal (old age, high income) and infant (female sex, preterm birth) factors.
Conclusions
This comprehensive analysis of the PHBPP in Korea demonstrates that the use of antivirals, breastfeeding, and cesarean section, combined with conventional immunoprophylaxis, has significantly reduced MTCT rates. These results are crucial for global HBV elimination and can help to guide HBV MTCT prevention strategies.

Citations

Citations to this article as recorded by

Redefining MTCT prevention strategies toward HBV elimination: Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”
Eunho Choi, Ji Hoon Kim, Young-Sun Lee
Clinical and Molecular Hepatology.2026; 32(2): 943. CrossRef

4,059 View
157 Download
1 Web of Science
Crossref

Reply to Correspondence

Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”: Shang-Chin Huang, Jia-Horng Kao; Clin Mol Hepatol 2026;32(1):e117-e118.
Published online May 13, 2025; DOI: https://doi.org/10.3350/cmh.2025.0500

4,033 View
28 Download

Editorials

Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Shang-Chin Huang, Jia-Horng Kao; Clin Mol Hepatol 2026;32(1):423-425.
Published online April 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0369

Citations

Citations to this article as recorded by

Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
Shang-Chin Huang, Jia-Horng Kao
Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Correspondence to editorial 1 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Rui Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology.2026; 32(1): e83. CrossRef
Steatosis Paradox: Unraveling Pathways of Suppressive Effect of Hepatic Steatosis on Hepatitis B Virus
Shang-Chin Huang, Jia-Horng Kao
Biomedical Journal.2026; : 100969. CrossRef

4,915 View
47 Download
Crossref

Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalently closed circular DNA minichromosome”: Mehrangiz Dezhbord, Kyun-Hwan Kim; Clin Mol Hepatol 2026;32(1):385-389.
Published online April 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0366

4,081 View
88 Download

Regulation of hepatitis B virus cccDNA by metabolic pathways: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”: Hyeong-Jin Cho, Sung-Gyoo Park; Clin Mol Hepatol 2026;32(1):381-384.
Published online March 12, 2025; DOI: https://doi.org/10.3350/cmh.2025.0255

Citations

Citations to this article as recorded by

Establishment and evaluation of an immortalized dzo kidney cell line
Wenkai Liu, Cong Xu, Jiamin Wang, Na Sun, Zhongren Ma, Jin Zhao, Jianguo Chen, You Li, Zilin Qiao
Scientific Reports.2025;[Epub] CrossRef

5,383 View
115 Download
Crossref

Viral hepatitis

Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”: Chih-Wen Wang, Ming-Lung Yu; Clin Mol Hepatol 2025;31(2):606-609.
Published online December 3, 2024; DOI: https://doi.org/10.3350/cmh.2024.1078

Citations

Citations to this article as recorded by

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clinical and Molecular Hepatology.2025; 31(2): e169. CrossRef

6,678 View
41 Download
1 Web of Science
Crossref

Reviews

Viral hepatitis

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B: Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto; Clin Mol Hepatol 2025;31(Suppl):S182-S195.
Published online November 21, 2024; DOI: https://doi.org/10.3350/cmh.2024.0837

Abstract
PDF

Chronic hepatitis B (CHB) poses a major global public health challenge and is a leading cause of cirrhosis and liver cancer. Hepatic steatosis is common in individuals with CHB compared to the non-CHB population and is particularly prevalent in hepatitis B virus (HBV)-endemic regions, affecting about one-third of CHB patients. The interaction between hepatic steatosis and CHB-related disease progression is complex and still under debate. Evidence demonstrates that co-existing steatosis may worsen liver fibrosis while paradoxically increasing the likelihood of achieving better HBV control. In particular, despite the association of steatotic liver disease (SLD) with lower HBV viral loads and higher rates of HBsAg seroclearance, the coexistence of CHB and SLD can potentially accelerate liver disease progression. Factors such as fat deposition, lipotoxicity, oxidative stress, and chronic inflammation in SLD may foster a pro-fibrotic and pro-carcinogenic environment, accelerating the disease progression. Additionally, loss of global DNA methylation, changes in the immune microenvironment, and genetic susceptibility further contribute to the development of CHB-related cirrhosis and hepatocellular carcinoma (HCC). This review examines the mechanisms driving liver disease progression and the heightened risk of cirrhosis and HCC in patients with concurrent CHB and steatotic liver disease, underscoring the importance of prioritizing antiviral therapy for CHB in addition to addressing SLD.

Citations

Citations to this article as recorded by

Letter to the editor on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
Sisi Yang, Zhenxuan Ma
Clinical and Molecular Hepatology.2026; 32(1): e4. CrossRef
Evaluation of PNPLA3 genetic variants in Egyptian HBV-infected patients concomitant with metabolic-associated steatotic liver disease (MASLD)
Mai Abd El-Meguid, Ghada M. Salum, Basma E. Fotouh, Naglaa Zayed, Shereen Abdel Alem, Ayman Yosry, Reham M. Dawood
Diagnostic Microbiology and Infectious Disease.2026; 114(2): 117105. CrossRef
Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study
Jing Liang, Xueqi Li, Guangwen Cheng, Huixiong Xu, Yuli Zhu, Zhe Ma, Dong Jiang, Hao Han, Lin Chen, Liyun Xue, Xiaohui Qiao, Hong Ding
Ultrasound in Medicine & Biology.2026; 52(1): 227. CrossRef
The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu
Frontiers in Immunology.2026;[Epub] CrossRef
Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id
Heejoon Jang, Won Kim
Clinical and Molecular Hepatology.2026; 32(1): 426. CrossRef
Progress in research on the hepatoprotective effects of C-21 steroidal glycosides from Baishouwu
Meitong Lu, Yongfang Ding, Yingyu Wang, Jinao Duan, Yunru Peng
Journal of Ethnopharmacology.2026; 360: 121211. CrossRef
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial
Hyunjae Shin, Youngsu Park, Byeong Geun Song, Won-Mook Choi, Hyung Joon Han, Youngwoo Lee, Tae-Jin Song, Jong-Eun Yeon, Young-Suk Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon, Jeong-Hoon Lee
Cancer Immunology, Immunotherapy.2026;[Epub] CrossRef
The nuclear transport machinery in hepatocellular carcinoma: From precancerous lesions to progression and therapeutic targeting
Hongwei Yang, Haomin Wu, Haonan Zhou, Shiqi Liu, Mohan Xu, Di Wu, Yifan Jin, Ruilin Xing, Huili Zhang, Guang Wang, Gang Wu
Genes & Diseases.2026; : 102065. CrossRef
The impact of the COVID-19 pandemic on liver health: exploring shifts in social and psychosocial determinants of steatosis and fibrosis
Yuan Zhao, Xuanhui Li, Jiacheng Cheng, Dongyu Hu, Huili Cao, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li
Frontiers in Medicine.2026;[Epub] CrossRef
Concurrent Steatotic Liver Disease and Prognosis After Curative Resection of Hepatocellular Carcinoma
Yan-Wen Liu, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, Yi-Hao Yen, Yuan-Hung Kuo, Hsin-Ming Wang, Ming-Chao Tsai
Journal of Hepatocellular Carcinoma.2026; Volume 13: 1. CrossRef
HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications
Xiaodong Shen, Hechen Huang, Jianpeng Sheng, Xiaofeng Tang
Clinical and Experimental Medicine.2026;[Epub] CrossRef
Regulatory Role of Ribosome Biogenesis-Related Genes in Hepatocellular Carcinoma Prognosis and Construction of a Risk Prediction Model
Shijing Tang, Hao Chen
Digestive Diseases and Sciences.2026;[Epub] CrossRef
Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB
Seong Hee Kang, Hyung Joon Yim, Seul Ki Han, Sun Young Yim, Tae Hyung Kim, Young‐Sun Lee, Seung Kak Shin, Young Kul Jung, Moon Young Kim, Ji Hoon Kim, Yeon Seok Seo, Oh. Sang Kwon, Jong Eun Yeon, Soon Koo Baik
Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
The multifaceted roles of interleukin-36 in liver diseases: from pathogenesis to therapeutic potential
Gui-Rong Rao, Shu-Ming Zhang, Xiao-Fei Yang, Li-Min Luo, Jian-Qi Lian, Ye Zhang
International Immunopharmacology.2026; 177: 116566. CrossRef
Steatosis Paradox: Unraveling Pathways of Suppressive Effect of Hepatic Steatosis on Hepatitis B Virus
Shang-Chin Huang, Jia-Horng Kao
Biomedical Journal.2026; : 100969. CrossRef
Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes
Qin Lou, Jiarong Cai, Jianhua Yin
Microorganisms.2026; 14(4): 853. CrossRef
Pollutants in Microenvironmental Cellular Interactions During Liver Inflammation Cancer Transition and the Application of Multi-Omics Analysis
Yulun Jian, Yuhan Li, Yanfeng Zhou, Wei Mu
Toxics.2025; 13(3): 163. CrossRef
Identification and evaluation of biomarkers for diagnosis of chronic hepatitis B using RNA-seq
Hong Hong, Xintong Han, Qiuxiang Hu, Huafeng Song, Bing Han
Virus Research.2025; 358: 199589. CrossRef
Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis
Won-Mook Choi, Wai-Kay Seto
Hepatology.2025;[Epub] CrossRef
Exosome in HBV infection: current concepts and future perspectives
XueLan Yuan, ChunXia Huang, Yan Ran
Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs
Angela Chau, Jie Li, Dae Won Jun, Yao‐Chun Hsu, Hidenori Toyoda, Ming‐Lun Yeh, Tsunamasa Watanabe, Takashi Honda, Huy Trinh, Akito Nozaki, Haruki Uojima, Toru Ishikawa, Daniel Q. Huang, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masanori Atsukawa, Ma
Journal of Viral Hepatitis.2025;[Epub] CrossRef
Preoperative HBsAg seroclearance affects long-term outcomes for hepatitis B virus-related hepatocellular carcinoma after liver resection: a multicenter analysis
Si-Yu Liu, Lin Zhu, Wen-Feng Lu, Gui-Lin Xie, Lei Liang, Jun-Wei Liu, Bin Ye, Mu-Gen Dai
BMC Cancer.2025;[Epub] CrossRef
Efficacy and safety of bifidobacterium triple viable capsules combined with entecavir in the treatment of Hepatitis B cirrhosis
Rongquan Liu, Yun Ji, Jie Zhang
Biomedical Papers.2025;[Epub] CrossRef
EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis
Jie You, Yihuan Huang, Chenhao Jiang, Jiaqi Xiao, Jiebin Zhang, Yasong Liu, Xin Sui, Yingcai Zhang, Jia Yao, Tongyu Lu
Journal of Translational Medicine.2025;[Epub] CrossRef
Prognostic Value of the PET/CT-Derived Maximum Standardized Uptake Value Combined with the Neutrophil–Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy
Tianyi Zhou, Chaoliu Dai
Current Oncology.2025; 33(1): 13. CrossRef

10,651 View
287 Download
22 Web of Science
Crossref

Viral hepatitis

Prospect of emerging treatments for hepatitis B virus functional cure: Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen; Clin Mol Hepatol 2025;31(Suppl):S165-181.
Published online November 14, 2024; DOI: https://doi.org/10.3350/cmh.2024.0855

Abstract
PDF

Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic hepatitis B (CHB). Nonetheless, functional cure is rarely attained with the current treatment modalities of nucleos(t)ide analogues (NUCs) and pegylated interferon alpha. Multiple novel virus-targeting agents and immunomodulators are under development for HBV with functional cure as the treatment goal. Among virus-targeting agents, antisense oligonucleotides and small-interfering RNAs are the most advanced in the developmental pipeline, and can induce potent and sustainable HBsAg suppression. The other virus-targeting agents have varying effects on HBsAg and HBV DNA, depending on the drug mechanism. In contrast, immunomodulators have modest effects on HBsAg and have limited roles in monotherapy. Multiple combination regimens incorporating RNA interference agents with immunomodulators have been studied through many ongoing clinical trials. These combination strategies demonstrate synergistic effects in inducing functional cure, and will likely be the future direction of development. Despite the promising results, research is warranted to optimize treatment protocols and to establish criteria for NUC withdrawal after novel therapies. Functional cure is now an attainable target in CHB, and the emerging novel therapeutics will revolutionize CHB management.

Citations

Citations to this article as recorded by

Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure
Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen
Gut.2026; 75(1): 119. CrossRef
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalentl
Mehrangiz Dezhbord, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2026; 32(1): 385. CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure
Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Clinical and Molecular Hepatology.2026; 32(1): 184. CrossRef
Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients
Yandan Wu, Yu Zhao, Ruixue Ji, Pinqing Li, Huijuan Chen, Fangping Yue, Yi Wu, Jie Qiu, Chuanlai Shen
Frontiers in Immunology.2026;[Epub] CrossRef
Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China
Yuchen Peng, Liping Liu, Xiaoping Wu
Annals of Medicine.2026;[Epub] CrossRef
Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B
Shuaibing Ying, Jinyao Dai, Qiudan Zhang, Yujing Wang, Yina Yu, Zhijuan Zhang, Shaohua Dong, Yichun Zhang, Haoyang Hu, Yuqi Hong, Yi Liu, Yuqi Guo, Haomin Yan, Yunqing Qiu, Yan Lou
Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Sodium taurocholate cotransporting polypeptide in HBV-related diseases: from underlying mechanisms to targeted therapies
Qiang Xie, Qingbo Liu, Xin Zheng, Leilei Fu, Hussein H. Aly, Bo Liu
Drug Discovery Today.2026; : 104664. CrossRef
Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect
Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu
Bioorganic & Medicinal Chemistry.2026; : 118662. CrossRef
CD16+ γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infection
Paulina E Schröter, Katja Steppich, Laura Fernández Carrera, Zheng Song, Sebastian Klein, Roni Souleiman, Melanie Urbanek-Quaing, Ayesha D Lietzau, Ansgar Schnieders, Erich Freyer, Birgit Bremer, Ximena León-Lara, Vicente Almeida, Rodrigo Gutierrez Jaureg
Gut.2026; : gutjnl-2025-337640. CrossRef
Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers
Liping Xu, Huaqun Zhang, Bingchen Jiang, Yuanying Jiang, Hui Lu
Pharmaceutics.2026; 18(4): 446. CrossRef
Repurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation
Samuel Chima Ugbaja, Siphathimandla Authority Nkabinde, Magugu Nkabinde, Nceba Gqaleni
Pharmaceuticals.2026; 19(4): 627. CrossRef
Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy”
Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Journal of Hepatology.2025; 82(5): e228. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Hepatology International.2025; 19(2): 304. CrossRef
Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider?
Shang-Chin Huang, Jia-Horng Kao
Expert Review of Gastroenterology & Hepatology.2025; 19(4): 371. CrossRef
Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase: A Systematic Review and Meta‐Analysis
Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You, Kevork M. Peltekian
Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Hepatitis B: Neue therapeutische Ansätze für eine funktionelle Heilung
Markus Cornberg, Ulrike Protzer
Deutsches Ärzteblatt Online.2025;[Epub] CrossRef
Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability
Yurong Yang, Fuling Xiao, Jianping Zuo, Li Yang, Youhong Hu, Wuhong Chen
Bioorganic & Medicinal Chemistry.2025; 128: 118259. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Hepatology International.2025; 19(4): 704. CrossRef
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure
Ana Verma, Raymond T. Chung
Current Opinion in HIV and AIDS.2025; 20(5): 449. CrossRef
Challenges and advances in clinical cure of chronic hepatitis B
Xu-Ling Liu, Yu-Lang Jiang, Ming-Yu Sun
World Chinese Journal of Digestology.2025; 33(9): 693. CrossRef
Small molecule HBV RNA destabilizing drugs: Drugs of the future or compounds from the past?
Timothy M. Block, Dimitar Gotchev, Yanming Du
Antiviral Research.2025; 244: 106288. CrossRef
Global strategies and actions to eliminate hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clinical and Molecular Hepatology.2025; 31(4): 1197. CrossRef
Morphometric and structural dynamic parameters of hepatitis viruses: implications for therapeutic and vaccine failure
Saganuwan Alhaji Saganuwan
Discover Viruses.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
Hepatoma Research.2025;[Epub] CrossRef

12,016 View
518 Download
15 Web of Science
Crossref

Correspondence

Hepatic neoplasm

Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”: Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer; Clin Mol Hepatol 2025;31(1):e44-e47.
Published online October 21, 2024; DOI: https://doi.org/10.3350/cmh.2024.0781

Citations

Citations to this article as recorded by

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Antonio Bertoletti, Anthony T Tan
Clinical and Molecular Hepatology.2025; 31(1): e113. CrossRef

4,930 View
60 Download
Crossref

Reply to Correspondence

Hepatic neoplasm

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”: Antonio Bertoletti, Anthony T Tan; Clin Mol Hepatol 2025;31(1):e113-e116.
Published online October 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0867

4,695 View
40 Download

Letter to the Editor

Viral hepatitis

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”: Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang; Clin Mol Hepatol 2025;31(1):e27-e30.
Published online August 7, 2024; DOI: https://doi.org/10.3350/cmh.2024.0602

Citations

Citations to this article as recorded by

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
Clinical and Molecular Hepatology.2025; 31(1): e108. CrossRef

7,486 View
69 Download
Crossref

Correspondence

Viral hepatitis

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”: Gi-Ae Kim, Seung Won Choi, Young-Suk Lim; Clin Mol Hepatol 2025;31(1):e108-e109.
Published online August 5, 2024; DOI: https://doi.org/10.3350/cmh.2024.0619

5,828 View
41 Download

Reply to Correspondence

Viral hepatitis

Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”: Beom Kyung Kim; Clin Mol Hepatol 2024;30(4):1044-1046.
Published online July 29, 2024; DOI: https://doi.org/10.3350/cmh.2024.0584

Citations

Citations to this article as recorded by

Prediction Model for Familial Aggregated HBV‐Associated Hepatocellular Carcinoma Based on Serum Biomarkers
Linmei Zhong, Guole Nie, Qiaoping Wu, Honglong Zhang, Haiping Wang, Jun Yan
Cancer Reports.2025;[Epub] CrossRef

5,079 View
31 Download
1 Web of Science
Crossref

Original Article

Viral hepatitis

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B: Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim; Clin Mol Hepatol 2024;30(4):793-806.
Published online July 19, 2024; DOI: https://doi.org/10.3350/cmh.2024.0252

Background/Aims
Serum hepatitis B virus (HBV) DNA levels and non-invasive liver fibrosis scores are significantly associated with hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. Nonetheless, the relationship between HBV DNA levels and liver fibrosis scores is unclear.
Methods
A historical cohort comprising 6,949 non-cirrhotic Korean CHB patients without significant alanine aminotransferase elevation was investigated. The association of HBV DNA levels with the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis (FIB)-4 score at baseline was analyzed using general linear models.
Results
In HBeAg-negative patients (n=4,868), HBV DNA levels correlated linearly with both APRI and FIB-4 scores. In contrast, in HBeAg-positive patients (n=2,081), HBV DNA levels correlated inversely with both APRI and FIB-4 scores. Across the entire cohort, a significant non-linear parabolic relationship was identified between HBV DNA levels and fibrosis scores, independent of age and other covariates. Notably, moderate viral loads (6–7 log10 IU/mL) corresponded to the highest APRI and FIB-4 scores (p<0.001). Over a median 10-year follow-up, 435 patients (6.3%) developed HCC. Higher APRI scores ≥0.5 and FIB-4 scores ≥1.45 were significantly associated with elevated HCC risk (p<0.001 for both). HBV DNA level remained a significant predictive factor for HCC development, even after adjusting for APRI or FIB-4 scores.
Conclusions
HBV viral load is significantly correlated with APRI and FIB-4 scores, and is also associated with HCC risk independent of those scores in CHB patients. These findings suggest that HBV DNA level is associated with hepatocarcinogenesis through both direct and indirect pathways.

Citations

Citations to this article as recorded by

Association between serum HBV DNA levels and liver fibrosis in chronic hepatitis B
Tao Fan, Jian Wang, Li Zhu, Ye Xiong, Shaoqiu Zhang, Jiacheng Liu, Chao Jiang, Shengxia Yin, Xin Tong, Guiyang Wang, Bei Jia, Juan Xia, Xiaomin Yan, Renling Yao, Yuxin Chen, Yu Shi, Xingxiang Liu, Yuanwang Qiu, Taoran Geng, Qun Zhang, Chuanwu Zhu, Chao Wu
Digestive and Liver Disease.2026; 58(4): 503. CrossRef
An interpretable machine learning model for prediction of significant liver fibrosis in comorbid chronic hepatitis B and nonalcoholic fatty liver disease: a retrospective development and validation study
Jiaping Gu, Jiale Chai
BMC Gastroenterology.2026;[Epub] CrossRef
Salvianolic acid C attenuates liver fibrosis and inhibites hepatic stellate cell activation by targeting FAP/TβRI/SMAD axis
Tao Sun, Xue Zheng, Liang Li, Jin Chu, Qiang Guo, Ning Yang, Xue Zhang, Xiaotong Li, Bowen Shi, Hongbin Zhang, Guodong Lü, Lufeng Cheng, Renyong Lin, Xiaojuan Bi
International Immunopharmacology.2026; 175: 116400. CrossRef
Correlation analysis of Th1/Th2 cytokines and liver fibrosis indicators in chronic hepatitis B patients
Chun Yu, Meiling Chen, Xiaonan Han, Yuhang Feng, Hongwei Sun, Hong Yang
Journal of Medical Biochemistry.2026; 45(4): 749. CrossRef
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang
Clinical and Molecular Hepatology.2025; 31(1): e27. CrossRef
Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
Clinical and Molecular Hepatology.2025; 31(1): e108. CrossRef
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, Chi-Yi Chen, Won-Mook Choi, Wonseok Kang, Gi-Ae Kim, Hyung Joon Kim, Yun Bin Lee, Jeong-Hoon Lee, Neung Hwa Park, So Young Kwon, Soo Young Park, Ji Hoon Kim, Gwang Hyeon Choi, Eun Sun Jang, Chien-Hung Chen, Yao-Ch
The Lancet Gastroenterology & Hepatology.2025; 10(4): 295. CrossRef
Aspartate aminotransferase-to-platelet ratio index as a novel predictor of early mortality in heat stroke patients: a multi-centre retrospective study
Min Wang, Yun Li, Yuan Cao, Meng-Meng Yang, Fu-Jing Liu, Jie Jiao, Sheng-Yuan Wang, Bin Song, Lu Wang, Yi-Qi Wu, Hong-Jun Kang
Annals of Medicine.2025;[Epub] CrossRef
Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
Journal of Gastroenterology and Hepatology.2025; 40(6): 1595. CrossRef
HBV activates hepatic stellate cells through RUNX2/ITGBL1 axis
Fengchun Shi, Wei Tan, Wei Huang, Fei Ye, Mingjie Wang, Yongxiang Wang, Xinxin Zhang, Demin Yu
Virology Journal.2025;[Epub] CrossRef
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo
Journal of Hepatology.2025; 83(2): 502. CrossRef
Geospatial patterns and socioeconomic determinants of the global acute viral hepatitis burden
Ke-Jie He, Guoyu Gong
Frontiers in Public Health.2025;[Epub] CrossRef
Reevaluating antiviral thresholds in HBV DNA-negative inactive HBsAg carriers: a multicenter histopathological analysis
Shan Ren, Sujun Zheng, Xinyang Zhang, Junliang Fu, Rongshan Fan, Qingfa Ruan, Wenqi Huang, Haibing Gao, Xiulan Xue, Fang Yang, Yao Xie, Minghui Li, Xinyue Chen
Virology Journal.2025;[Epub] CrossRef
Evaluating Non-Invasive Biomarkers and Composite Scores for Liver Fibrosis Diagnosis in Hepatitis B and C Infections
Tamer A. Addissouky, Ibrahim El Tantawy El Sayed, Ayman E. El Agroudy, Yuliang Wang
SN Comprehensive Clinical Medicine.2025;[Epub] CrossRef
Viral Load–Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B
Gi-Ae Kim, Young-Suk Lim
Annals of Internal Medicine.2025; 178(9): 1365. CrossRef
Integrated Assessment of Liver Disease Severity and Viral Load in Human Immunodeficiency Virus–Hepatitis B Virus Coinfected Individuals: Utilizing Aspartate Aminotransferase/Platelet Ratio Index and FIB-4 Biomarkers Alongside Real-time Polymerase Chain Re
Hiba Sami, Mohd Asaad, Sohail Ansari, Syed Haider Mehdi Husaini, Mohammad Azam Khan, Parvez Anwar Khan, Nazish Fatima, Haris Manzoor Khan
Journal of Applied Sciences and Clinical Practice.2025; 6(3): 89. CrossRef
Revised REACH-B Model for Hepatocellular Carcinoma Risk Prediction in Patients With Chronic Hepatitis B
Ju Dong Yang, Patrick S. Kamath
Annals of Internal Medicine.2024; 177(10): 1435. CrossRef
Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection
Kazuto Tajiri, Yuka Hayashi, Aiko Murayama, Nozomu Muraishi, Masami Minemura, Ichiro Yasuda
Viruses.2024; 17(1): 44. CrossRef

9,205 View
259 Download
15 Web of Science
Crossref

Reply to Correspondence

Viral hepatitis

Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”: Cho-Rong Lee, Sung-Gyoo Park; Clin Mol Hepatol 2024;30(4):1053-1054.
Published online July 17, 2024; DOI: https://doi.org/10.3350/cmh.2024.0572

Citations

Citations to this article as recorded by

Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Cho-Rong Lee, Sung-Gyoo Park
Clinical and Molecular Hepatology.2024; 30(4): 1053. CrossRef

5,473 View
62 Download
1 Web of Science
Crossref

Editorial

Viral hepatitis

Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”: Cho-Rong Lee, Sung-Gyoo Park; Clin Mol Hepatol 2024;30(4):724-727.
Published online July 3, 2024; DOI: https://doi.org/10.3350/cmh.2024.0465

Citations

Citations to this article as recorded by

Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression
Guangmei Li, Dengju Li, Xiaojian Zhu
Frontiers in Immunology.2025;[Epub] CrossRef
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Mehrangiz Dezhbord, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2024; 30(4): 1028. CrossRef

5,297 View
83 Download
2 Web of Science
Crossref

Original Article

Hepatic neoplasm

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting: Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du; Clin Mol Hepatol 2024;30(4):735-755.
Published online May 29, 2024; DOI: https://doi.org/10.3350/cmh.2024.0058

Background/Aims
Hepatitis B virus (HBV)-DNA integration in HBV-related hepatocellular carcinoma (HBV-HCC) can be targeted by HBV-specific T cells. SCG101 is an autologous, HBV-specific T-cell product expressing a T-cell receptor (TCR) after lentiviral transduction recognizing the envelope-derived peptide (S_20-28) on HLA-A2. We here validated its safety and efficacy preclinically and applied it to an HBV-related HCC patient (NCT05339321).
Methods
Good Manufacturing Practice-grade manufactured cells were assessed for off-target reactivity and functionality against hepatoma cells. Subsequently, a patient with advanced HBV-HCC (Child-Pugh class A, Barcelona Clinic Liver Cancer stage B, Eastern Cooperative Oncology Group performance status 0, hepatitis B e antigen-, serum hepatitis B surface antigen [HBsAg]+, HBsAg+ hepatocytes 10%) received 7.9×10⁷ cells/kg after lymphodepletion. Safety, T-cell persistence, and antiviral and antitumor efficacy were evaluated.
Results
SCG101, produced at high numbers in a closed-bag system, showed HBV-specific functionality against HBV-HCC cells in vitro and in vivo. Clinically, treatment was well tolerated, and all adverse events, including transient hepatic damage, were reversible. On day 3, ALT levels increased to 1,404 U/L, and concurrently, serum HBsAg started decreasing by 3.84 log¹⁰ and remained <1 IU/mL for over six months. HBsAg-expressing hepatocytes in liver biopsies were undetectable after 73 days. The patient achieved a partial response according to modified RECIST with a >70% reduction in target lesion size. Transferred T cells expanded, developed a stem cell-like memory phenotype, and were still detectable after six months in the patient’s blood.
Conclusions
SCG101 T-cell therapy showed encouraging efficacy and safety in preclinical models and in a patient with primary HBV-HCC and concomitant chronic hepatitis B with the capability to eliminate HBsAg⁺ cells and achieve sustained tumor control after single dosing.

Citations

Citations to this article as recorded by

Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial
Xiang'an Wu, Dongmei Quan, Wei Li, Karin Wisskirchen, Wei Wu, Yuhong Zhou, Yun-Peng Liu, Xueshuai Wan, Xiaorui Wang, Xuxu Zhang, Lu Yang, Mengyao Zheng, Ke Zhang, Ulrike Protzer, Shunda Du, Xiujuan Qu
Gut.2026; 75(1): 147. CrossRef
Combination therapies for chronic hepatitis B in the era of emerging novel drugs
Dandan Weng, Chenxi Zhang, Qunyan Wei, Lukan Zhang, Xinya Zang, Guancheng Huang, Zhujun Cao, Qing Xie
Hepatology International.2026; 20(1): 9. CrossRef
Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches
Prashant Tiwari, Istuti Saraswat, Jyoti Gupta
Current Microbiology.2026;[Epub] CrossRef
HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications
Xiaodong Shen, Hechen Huang, Jianpeng Sheng, Xiaofeng Tang
Clinical and Experimental Medicine.2026;[Epub] CrossRef
The Impact of Hepatitis B Virus on the Tumor Microenvironment of Hepatocellular Carcinoma and Therapeutic Strategies
Ximing Li, Zijie Wu, Zhijun He, Yanchao Xu, Wenbin Xie, Shitong Huang, Lingxiao Chen, Zheng Gao, Siqi Tang, Xiangdong Gao, Hong Tian
Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Antonio Bertoletti, Anthony T Tan
Clinical and Molecular Hepatology.2025; 31(1): e113. CrossRef
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer
Clinical and Molecular Hepatology.2025; 31(1): e44. CrossRef
T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells
Thikra Majid Muhammed, Saade Abdalkareem Jasim, Ahmed Hussein Zwamel, Safia Obaidur Rab, Suhas Ballal, Abhayveer Singh, Anima Nanda, Subhashree Ray, Ahmed Hjazi, Hatif Abdulrazaq Yasin
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(8): 10007. CrossRef
Hepatitis B: Neue therapeutische Ansätze für eine funktionelle Heilung
Markus Cornberg, Ulrike Protzer
Deutsches Ärzteblatt Online.2025;[Epub] CrossRef
Exploration of the role of immune cells and cell therapy in hepatocellular carcinoma
Tao Zhang, Cong Ren, Zhanyu Yang, Ning Zhang, Haowen Tang
Frontiers in Immunology.2025;[Epub] CrossRef
Viral oncogenesis in cancer: from mechanisms to therapeutics
Qing Xiao, Yi Liu, Tingting Li, Chaoyu Wang, Sanxiu He, Liuyue Zhai, Zailin Yang, Xiaomei Zhang, Yongzhong Wu, Yao Liu
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
Unlocking T‐Cell Plasticity in the Tumor Microenvironment: Implications for Cancer Progression and Therapeutic Strategies
Xiao‐Hong Ding, Xue‐Pei Li, Fenfang Chen, Han Wang, Yi‐Zhou Jiang
MedComm – Oncology.2025;[Epub] CrossRef
Immunotherapy for hepatocellular carcinoma
Zhiqi Guan, Guiqi Zhu, Weiren Liu, Yinghong Shi
Clinical Cancer Bulletin.2025;[Epub] CrossRef
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases
Elmar Jaeckel, Scott L. Friedman, Michael Hudecek, Ulrike Protzer
Journal of Hepatology.2025; 83(5): 1156. CrossRef
Adoptive T-cell therapy for virus-associated diseases
Corey Smith, Rajiv Khanna, Graeme N. Forrest
Clinical Microbiology Reviews.2025;[Epub] CrossRef
CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183–91/HLA-A *0201 exhibit potent activity against HBV-HCC
Fengling Wang, Jiaqian Li, Yong Huang, Feiyang Yan, Haozhan Gao, Weilin Zhou, Xinyu Gu, Dan Li, Yalan Zhang, Jing Li, Yuening Yang, Jiangping Yang, Mengxi Zhang, Jinrong Yang, Shimao Qi, Wei Wang
OncoImmunology.2025;[Epub] CrossRef
Targeting archetypes of viral-driven cancers with immunotherapy: a perspective on immunogenicity within the tumor microenvironment
Keene Lee, Seohyun Kim, Junzhe Zhao, Shi Yong Neo
Frontiers in Immunology.2025;[Epub] CrossRef
T cells engineered to carry a high-affinity HBV-specific T cell receptor: a potent weapon against advanced HBV-related HCC
Robert Thimme, Christoph Neumann-Haefelin
Gut.2025; : gutjnl-2025-336452. CrossRef
Do the therapeutic vaccines hold hope for the treatment of hepatitis B?
Qiujing Yan, Xinghuan Fu, Yan Wang, Guiqiang Wang
Hepatology International.2025; 19(6): 1320. CrossRef
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology
Shahzada Khan, Jeremy Lum, Heather Stephenson, Pawan Bir Kohli, David Mortenson, Dhivya Ramakrishnan, Magdeleine Hung, Sheng Ding, Elbert Seto, Sabrina Lu, Randy Yen, Debi Jin, Brian Lee, Sheila Clancy, Nicole Schirle Oakdale, Nikolai Novikov, Don Kang, R
mAbs.2025;[Epub] CrossRef
Adoptive cell therapy for HBV-associated liver diseases
Youxi Zhou, Kaizhao Chen, Yang Zhang, Hongwei Cheng, Shuaishuai Zhang
Biomedical Technology.2025; 12: 100116. CrossRef
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma
Subhrojyoti Mukherjee, Manish Kumar
Expert Review of Anticancer Therapy.2025; : 1. CrossRef
Recent Advances in Immune-based Therapy for Hepatocellular Carcinoma
Kyung Won Park, Tae Hoon Park, Eun Ji Jang, Pil Soo Sung
Journal of Digestive Cancer Research.2024; 12(2): 115. CrossRef
Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcin
Antonio Bertoletti, Anthony T Tan
Clinical and Molecular Hepatology.2024; 30(4): 728. CrossRef

9,920 View

482 Download

23 Web of Science

Crossref

Editorials

Steatotic liver disease

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol 2024;30(4):705-708.
Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

PDF

Citations

Citations to this article as recorded by

Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2025; 31(1): 261.     CrossRef
Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities
Wania Sultan, Haider Ashfaq, Hamza Ashraf, Ahmad Khan, Ayman Omair Hashmi, Muhammad Omar Larik, Maheen Zahid, Yasir Majeed, Pratik Bhattarai, Ashujot K. Dang, Ahmed Ali Aziz, Hafiz Muhammad Sharjeel Arshad
JGH Open.2025;[Epub]     CrossRef
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy
Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li
Clinical and Molecular Hepatology.2024; 30(4): 965.     CrossRef
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George
Hepatology International.2024; 18(6): 1740.     CrossRef

6,242 View

82 Download

4 Web of Science

Crossref

Viral hepatitis

Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”

Hae Lim Lee, Jeong Won Jang

Clin Mol Hepatol 2024;30(4):692-694.
Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0346

PDF

Citations

Citations to this article as recorded by

Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability
Yurong Yang, Fuling Xiao, Jianping Zuo, Li Yang, Youhong Hu, Wuhong Chen
Bioorganic & Medicinal Chemistry.2025; 128: 118259.     CrossRef

4,793 View

74 Download

1 Web of Science

Crossref

Original Articles

Viral hepatitis

Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction

Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim

Clin Mol Hepatol 2024;30(3):539-560.
Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0060

Abstract

PDF
Supplementary Material

Background/Aims
The major histocompatibility class II (MHC II) transactivator, known as CIITA, is induced by Interferon gamma (IFN-γ) and plays a well-established role in regulating the expression of class II MHC molecules in antigen-presenting cells.
Methods
Primary human hepatocytes (PHH) were isolated via therapeutic hepatectomy from two donors. The hepatocellular carcinoma (HCC) cell lines HepG2 and Huh7 were used for the mechanistic study, and HBV infection was performed in HepG2-NTCP cells. HBV DNA replication intermediates and secreted antigen levels were measured using Southern blotting and ELISA, respectively.
Results
We identified a non-canonical function of CIITA in the inhibition of hepatitis B virus (HBV) replication in both HCC cells and patient-derived PHH. Notably, in vivo experiments demonstrated that HBV DNA and secreted antigen levels were significantly decreased in mice injected with the CIITA construct. Mechanistically, CIITA inhibited HBV transcription and replication by suppressing the activity of HBV-specific enhancers/promoters. Indeed, CIITA exerts antiviral activity in hepatocytes through ERK1/2-mediated down-regulation of the expression of hepatocyte nuclear factor 1α (HNF1α) and HNF4α, which are essential factors for virus replication. In addition, silencing of CIITA significantly abolished the IFN-γ-mediated anti-HBV activity, suggesting that CIITA mediates the anti-HBV activity of IFN-γ to some extent. HBV X protein (HBx) counteracts the antiviral activity of CIITA via direct binding and impairing its function.
Conclusions
Our findings reveal a novel antiviral mechanism of CIITA that involves the modulation of the ERK pathway to restrict HBV transcription. Additionally, our results suggest the possibility of a new immune avoidance mechanism involving HBx.

Citations

Citations to this article as recorded by

The Role of CD4+ T Helper Cell Subsets in Hepatocellular Carcinoma: Implications for Tumour Progression and Immunotherapy
Jijie Shao, Jintong Na, Honghua Huang, Lei Xiao, Fengqiu Dang, Rongshun Zheng, Liping Zhong, Yongxiang Zhao
Cells.2026; 15(4): 350.     CrossRef
DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs
Christiane Loerch, Wasco Wruck, Annika Wittich, Rabea Hokamp, Julian Reiss, Ole Pless, James Adjaye, Nina Graffmann
Frontiers in Cell and Developmental Biology.2026;[Epub]     CrossRef
Cytotoxic CD4+ T cells: origin, biological functions, diseases and therapeutic targets
Longyong Lai, Shuan Ran, Yuan Li, Jikai Cui, Xi Zhang, Jizhang Yu, Yanqiang Zou, Cheng Zhou, Jiahong Xia, Jie Wu
Signal Transduction and Targeted Therapy.2026;[Epub]     CrossRef
IFI35 suppresses the transcription of hepatitis B virus cccDNA minichromosome via promoting HNF4α proteasomal degradation
Nayeon Kim, Jae Jin Shin, Jae Won Oh, Juhee Won, Ah Ram Lee, Mehrangiz Dezhbord, Jeongwoo Park, Ki-Young Lee, Dong-Sik Kim, Kwang Pyo Kim, Kyun-Hwan Kim
Journal of Biomedical Science.2026;[Epub]     CrossRef
Impact of VHSV on CIITA-mediated MHCII expression and antigen presentation in largemouth bass
Xiaobing Lu, Ziling Qin, Zhe Hu, Hao Huang, Jie Su, Xiaoru Zhang, Meisheng Yi, Kuntong Jia
Fish & Shellfish Immunology.2025; 162: 110336.     CrossRef
Viral oncogenesis in cancer: from mechanisms to therapeutics
Qing Xiao, Yi Liu, Tingting Li, Chaoyu Wang, Sanxiu He, Liuyue Zhai, Zailin Yang, Xiaomei Zhang, Yongzhong Wu, Yao Liu
Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B
Xiao Ma, Tengda Huang, Yujia Song, Hongyuan Pan, Ao Du, Xinyi Zhou, Yong Zeng, Kefei Yuan, Xiaosheng Tan
PLOS One.2025; 20(5): e0323708.     CrossRef
Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells
Enis Kostallari, Robert F. Schwabe, Adrien Guillot
Cellular & Molecular Immunology.2025; 22(10): 1205.     CrossRef
Gender-specific alteration of steroid metabolism and its impact on viral replication in a mouse model of hepatitis B virus infection
Eun-Sook Park, Juhee Won, Sung Hyun Ahn, Ah Ram Lee, Donghyo Lee, Ju-Yeon Moon, Man Ho Choi, Kyun-Hwan Kim
Animal Cells and Systems.2024; 28(1): 466.     CrossRef
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Cho-Rong Lee, Sung-Gyoo Park
Clinical and Molecular Hepatology.2024; 30(4): 724.     CrossRef
Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA
Deok-Hwa Seo, Wonhee Hur, Juhee Won, Ji-Won Han, Seung-Kew Yoon, Songmee Bae, Kyun-Hwan Kim, Pil-Soo Sung
Viruses.2024; 16(12): 1890.     CrossRef

8,803 View

306 Download

14 Web of Science

Crossref

Viral hepatitis

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol 2024;30(3):500-514.
Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

Abstract

PDF
Supplementary Material

Background/Aims
Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared the risks of EHM and intrahepatic malignancy (IHM) between entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment.
Methods
Using data from the National Health Insurance Service of Korea, this nationwide cohort study included treatment-naïve CHB patients who initiated ETV (n=24,287) or TDF (n=29,199) therapy between 2012 and 2014. The primary outcome was the development of any primary EHM. Secondary outcomes included overall IHM development. E-value was calculated to assess the robustness of results to unmeasured confounders.
Results
The median follow-up duration was 5.9 years, and all baseline characteristics were well balanced after propensity score matching. EHM incidence rate differed significantly between within versus beyond 3 years in both groups (P<0.01, Davies test). During the first 3 years, EHM risk was comparable in the propensity score-matched cohort (5.88 versus 5.84/1,000 person-years; subdistribution hazard ratio [SHR]=1.01, 95% confidence interval [CI]=0.88–1.17, P=0.84). After year 3, however, TDF was associated with a significantly lower EHM incidence compared to ETV (4.92 versus 6.91/1,000 person-years; SHR=0.70, 95% CI=0.60–0.81, P<0.01; E-value for SHR=2.21). Regarding IHM, the superiority of TDF over ETV was maintained both within (17.58 versus 20.19/1,000 person-years; SHR=0.88, 95% CI=0.81–0.95, P<0.01) and after year 3 (11.45 versus 16.20/1,000 person-years; SHR=0.68, 95% CI=0.62–0.75, P<0.01; E-value for SHR=2.30).
Conclusions
TDF was associated with approximately 30% lower risks of both EHM and IHM than ETV in CHB patients after 3 years of antiviral therapy.

Citations

Citations to this article as recorded by

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs
Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
Clinical and Molecular Hepatology.2025; 31(1): e19.     CrossRef
The critical role of ferroptosis in virus-associated hematologic malignancies and its potential value in antiviral-antitumor therapy
Miao Miao, Yuelei Chen, Xuehan Wang, Shengyang Li, Rong Hu
Virulence.2025;[Epub]     CrossRef
Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent
Hyuk Kim, Jae‐Young Kim, Hyun Bin Choi, Ji‐Soo Lee, Yoon E. Shin, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
Journal of Medical Virology.2025;[Epub]     CrossRef
Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019–2024
Tao Liu, Zhihao Zhao, Jiao Wang, Xiaoying Chen, Jinhao Huang, Weiwei Jiang, Yunhu Yu, Xide Zhu, Kaijie Wang, Kun Lin, Hu Qin, Baixiang Peng, Guohe Zhang, Zhiyong Liu, Weiliang Chen, Jun Shen, Baozhi Chen, Shengjie Li, Mingqi Liu, Wanqiang Su, Wanhai Ding,
The Lancet Regional Health - Western Pacific.2025; 63: 101688.     CrossRef
Association between atherogenic index of plasma and incident aortic disease: a population-based prospective analysis
Cuihong Tian, Xiao Wang, Liang Tao, Wanyi Wei, Xuan Zhang, Haoxian Tang, Yequn Chen, Xuerui Tan
Open Heart.2025; 12(2): e003511.     CrossRef
Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study”
Yewan Park, Dong Hyun Sinn
Clinical and Molecular Hepatology.2024; 30(4): 718.     CrossRef
Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B
Tong Sun, Hongbo Chi, Jing Wang, Yufen Zheng, Hongguo Zhu, Jingxian Zhao, Kai Zhou, Mengyuan Chen, Donglian Wang, Tao-Hsin Tung, Jiaqin Xu, Bo Shen
BMC Infectious Diseases.2024;[Epub]     CrossRef

8,650 View

227 Download

6 Web of Science

Crossref

Viral hepatitis

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

Clin Mol Hepatol 2024;30(3):375-387.
Published online March 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0535

Abstract

PDF
Supplementary Material

Background/Aims
Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of EDP-514 in treatment-naive viremic patients with HBeAgpositive or -negative chronic HBV infection.
Methods
Patients with HBsAg detectable at screening and at least 6 months previously were eligible. HBeAg-positive and -negative patients had a serum/plasma HBV DNA level ≥20,000 and ≥2,000 IU/mL, respectively. Twenty-five patients were randomized to EDP-514 200 (n=6), 400 (n=6) or 800 mg (n=7) or placebo (n=6) once daily for 28 days.
Results
A dose-related increase in EDP-514 exposure (AUC_last and C_max) was observed across doses. At Day 28, mean reductions in HBV DNA were –2.9, –3.3, –3.5 and –0.2 log₁₀ IU/mL with EDP-514 200 mg, 400 mg, 800 mg, and placebo groups, respectively. The corresponding mean change from baseline for HBV RNA levels was –2.9, –2.4, –2.0, and –0.02 log₁₀ U/mL. No virologic failures were observed. No clinically meaningful changes from baseline were observed for HBsAg, HBeAg or HBcrAg. Nine patients reported treatment emergent adverse events of mild or moderate severity with no discontinuations, serious AEs or deaths.
Conclusions
In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.

Citations

Citations to this article as recorded by

Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review
He-ming Sun, Xing-yu Wang, Hong-qin Xu, Yan-hang Gao
Infectious Diseases and Therapy.2026; 15(4): 959.     CrossRef
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis
Jing Chen, Dong Ji, Jidong Jia, Hui Zhuang, Xinxin Zhang, Fu-Sheng Wang, Wenhong Zhang, Xiaoguang Dou, Tawesak Tanwandee, Shiv Kumar Sarin, Rakhi Maiwall, Manoj Kumar, George Boon-Bee Goh, Hasmik Ghazinyan, Anuchit Chutaputti, Pei-Jer Chen, Hong You, Ming
Hepatology International.2025; 19(4): 773.     CrossRef
Mise à jour concernant le traitement des hépatites virales
Marie Ongaro, Francesco Negro
Schweizer Gastroenterologie.2025; 6(2): 46.     CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators
Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu
Drug Discovery Today.2025; 30(10): 104458.     CrossRef
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”
Hae Lim Lee, Jeong Won Jang
Clinical and Molecular Hepatology.2024; 30(4): 692.     CrossRef

9,077 View

163 Download

4 Web of Science

Crossref

Viral hepatitis

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee

Clin Mol Hepatol 2023;29(3):794-809.
Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0057

Abstract

PDF
Supplementary Material

Background/Aims
Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients.
Methods
This study comprised 928 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at two referral centers in Korea. All patients with CHB received antiviral treatment. Time-to-progression (TTP) and overall survival (OS) were the primary and secondary endpoints, respectively.
Results
Among the 928 patients in this study, 82 were hepatitis B surface antigen (HBsAg)-positive (the CHB group) and 846 were HBsAg-negative (the non-CHB group). The median follow-up time was 50.5 months (interquartile range [IQR]=25.6–69.7 months). Multivariable analyses showed longer TTP in the CHB group than the non-CHB group both before inverse probability of treatment weighting (IPTW; adjusted hazard ratio [aHR]=0.49, 95% confidence interval [CI]=0.29–0.82, p=0.007) and after IPTW (aHR=0.42, 95% CI=0.26–0.70, p<0.001). The CHB group also had a longer OS than the non-CHB group both before IPTW (HR=0.55, 95% CI=0.33–0.92, log-rank p=0.02) and after IPTW (HR=0.53, 95% CI=0.32–0.99, log-rank p=0.02). Although liver-related deaths did not occur in the non-CHB group, two deaths occurred in the CHB group due to hepatocellular carcinoma and acute liver failure, respectively.
Conclusions
Our findings indicate that HBV-associated DLBCL patients receiving antiviral treatment have significantly longer TTP and OS after R-CHOP treatment than HBV-unassociated DLBCL patients.

Citations

Citations to this article as recorded by

Chronic hepatitis b coinfection and survival in pediatric T-ALL: A propensity-matched analysis
Yutong Zhang, Ruihong Wu, Yuan Zhang, Yufei Zhao, Xiaodan Zhong, Xianmei Jin, Chao Zhang, Jian Chang
iScience.2026; 29(1): 114319.     CrossRef
Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”
Chi Hsiao, Yung-Po Liaw
Clinical and Molecular Hepatology.2023; 30(1): 109.     CrossRef

8,620 View

186 Download

3 Web of Science

Crossref

Review

Viral hepatitis

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol 2023;29(4):869-890.
Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

Abstract

PDF

Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis B surface antigen (HBsAg). As an alternative strategy, finite NA therapy without the prerequisite of HBsAg seroclearance has been proposed to allow treatment cessation in patients with sustained undetectable HBV viremia for two to three years. However, reactivation of viral replication almost always follows NA withdrawal. Whereas HBV reactivation might facilitate HBsAg seroclearance in some, it could lead to serious acute flare-ups in a certain proportion of patients. Occurrence and consequences of NA withdrawal flares are complicated with various factors involving the virus, host, and treatment. Accurate risk prediction for severe flares following NA cessation is essential to ensure patient safety. The risks of life-threatening flares in patients who discontinued NA according to the stopping rules of current guidelines or local reimbursement policies have recently been quantitatively estimated in large-scale studies, which also provided empirical evidence to help identify vulnerable patients at risk of devastating outcomes. Moreover, risk predictors were further explored and validated to hopefully aid in patient selection and management. In this narrative review with a focus on patient safety, we summarize and discuss current literature on the incidence of severe flares following NA cessation, risk stratification for candidate selection, rules of posttreatment monitoring, and indications for treatment resumption. We also share our thoughts on the limitations of existing knowledge and suggestions for future research.

Citations

Citations to this article as recorded by

Chronic Hepatitis B Infection: Patient Guidance
Lung‐Yi Mak, Jimmy Che‐To Lai, Ken Liu, Rashid Lui, Sakkarin Chirapongsathorn, Kuo Chao Yew, Mara Teresa Panlilio, Cosmas Rinaldi Adithya Lesmana, Ruveena Bhavani Rajaram, Liang Shen, Desmond Cheung, Lung‐Fai Wong, Hye Won Lee, Madhumita Premkumar, Anand
Journal of Gastroenterology and Hepatology.2026; 41(1): 61.     CrossRef
Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B
Yingying Zhang, Xiu Han, Chengyu Xu, Yahui Song, Jinghan Zhu, Ruoran Zhou, Yiling Chen, Mingming Liu, Junchi Xu, Xiangwei Wu, Qingzhen Han, Zutao Chen
Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
Epstein–Barr Virus and Hepatitis E Virus in an Immunocompetent Adult: A Rare Case Report
Philippe Attieh, Antonio Al Hazzouri, Karam Karam, Ihab I. El Hajj, Elias Fiani
Clinical Case Reports.2026;[Epub]     CrossRef
Research Progress on the Recompensation of Liver Cirrhosis
源高
Advances in Clinical Medicine.2026; 16(03): 2709.     CrossRef
Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
Ying‐Nan Tsai, Jia‐Ling Wu, Cheng‐Hao Tseng, Tzu‐Haw Chen, Ying‐Chu Chung, Mindie H. Nguyen, Jaw‐Town Lin, Katsuya Nagaoka, Yasuhito Tanaka, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2026;[Epub]     CrossRef
Nucleos(t)ide Analog Treatment Discontinuation in Chronic Hepatitis B Virus Infection: A Systematic Literature Review
Robert Gish, Kosh Agarwal, Anadi Mahajan, Supriya Desai, Saifuddin Kharawala, Rob Elston, Joyeta Das, Stuart Kendrick, Vera Gielen
Gastro Hep Advances.2025; 4(1): 100536.     CrossRef
Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Scientific Reports.2025;[Epub]     CrossRef
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
Ying‐Nan Tsai, Jia‐Ling Wu, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2025; 61(7): 1244.     CrossRef
Association Between Elevation of Serum Alanine Aminotransferase and HBsAg Seroclearance After Nucleos(t)ide Analog Withdrawal
Ying‐Nan Tsai, Jia‐Ling Wu, Cheng‐Hao Tseng, Shang‐Chen Tseng, Chih‐Lung Hung, Mindie H. Nguyen, Jaw‐Town Lin, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2025; 61(7): 1208.     CrossRef
Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
Ying‐Nan Tsai, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2025; 61(8): 1424.     CrossRef
Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B
Cheng‐Hao Tseng, Teng‐Yu Lee, Chi‐Yi Chen, Chung‐Feng Huang, Po‐Yueh Chen, Tyng‐Yuan Jang, Tzeng‐Huey Yang, Chia‐Ching Wu, Yao‐Chun Hsu
Journal of Gastroenterology and Hepatology.2025; 40(5): 1245.     CrossRef
Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clinical and Molecular Hepatology.2025; 31(2): e169.     CrossRef
Impact of nucleos(t)ide analogue therapy on the incidence of Alzheimer’s disease in patients with chronic hepatitis B virus infection
Jihye Lim, Hyundam Gu, Hyunji Sang, Su Jin Jeong, Ha Il Kim
Alzheimer's Research & Therapy.2025;[Epub]     CrossRef
Association of nucleos(t)ide analogue therapy with Parkinson disease in chronic hepatitis B patients
Jihye Lim, Hyo Young Lee, Hyunji Sang, Su Jin Jeong, Ha Il Kim
Scientific Reports.2025;[Epub]     CrossRef
Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study
Shinya Kawamatsu, Kiran K. Rai, Vera Gielen, Amisha Patel, Olivia Massey, Seth W. Anderson, Yutaka Handa, Ethan Yichen Lee, Poppy Payne, Isabel Jimenez, Kejsi Begaj, Shayon Salehi, Jun Inoue, Afisi S. Ismaila
Journal of Viral Hepatitis.2025;[Epub]     CrossRef
Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
Scientific Reports.2025;[Epub]     CrossRef
Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B
Lu Zhang, Yu Cao, Sijing Zhuang, Jingjing Sun, Qiao Tong, Jianjun Xi, Shourong Liu, Rangxiao Zhuang
Frontiers in Pharmacology.2025;[Epub]     CrossRef
Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir
Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Scientific Reports.2025;[Epub]     CrossRef
Global strategies and actions to eliminate hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clinical and Molecular Hepatology.2025; 31(4): 1197.     CrossRef
Letter: Estimating the incidence of HBsAg seroclearance after cessation of tenofovir and entecavir ‐ potential influence of censored observation
Ying‐Nan Tsai, Jia‐Ling Wu, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2024; 59(1): 136.     CrossRef
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research
Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu
Clinical and Molecular Hepatology.2024; 30(2): 276.     CrossRef
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
Chen-Te Huang, Tai-Chung Tseng
Clinical and Molecular Hepatology.2024; 30(2): 154.     CrossRef
Finite therapy of chronic hepatitis B infection: Cons
Yao-Chun Hsu
Clinical Liver Disease.2024;[Epub]     CrossRef
Current perspectives of viral hepatitis
Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
Extended analysis on peripheral blood cytokines correlated with hepatitis B virus viral load in chronically infected patients – a systematic review and meta-analysis
Marina Manea, Ion Mărunțelu, Ileana Constantinescu
Frontiers in Medicine.2024;[Epub]     CrossRef
Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis
Stephen Sinclair, Sean Shearen, Youssef Ghobrial, George Trad, Syed Abdul Basit, David Shih, John K. Ryan
Viruses.2024; 16(10): 1531.     CrossRef
Real‐World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation
Jie Wang, He Jiang, Guoqi Zhang, Xiahong Dai, Hainv Gao, Lanjuan Li
Journal of Medical Virology.2024;[Epub]     CrossRef
Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population‐based cohort study
Yao‐Chun Hsu, Yi‐Hsian Lin, Teng‐Yu Lee, Mindie H. Nguyen, Cheng‐Hao Tseng, Hsiu J. Ho, Feng‐Yu Kao, Jaw‐Town Lin, Chen‐Yi Wu, Chun‐Ying Wu
Alimentary Pharmacology & Therapeutics.2023; 58(4): 463.     CrossRef
Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study. Authors' reply
Yao‐Chun Hsu, Chun‐Ying Wu
Alimentary Pharmacology & Therapeutics.2023; 58(5): 550.     CrossRef
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply
Yao‐Chun Hsu, Mindie H. Nguyen, Chun‐Ying Wu
Alimentary Pharmacology & Therapeutics.2023; 58(7): 733.     CrossRef

10,905 View

248 Download

25 Web of Science

Crossref

Editorial

Viral hepatitis

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol 2023;29(2):363-366.
Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

PDF

Citations

Citations to this article as recorded by

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon
Clinical and Molecular Hepatology.2024; 30(3): 500.     CrossRef
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2023; 29(3): 794.     CrossRef

7,625 View

107 Download

2 Web of Science

Crossref

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol 2023;29(2):320-331.
Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

Abstract

PDF

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma, its interactions with the hepatitis B virus (HBV) and clinical impacts seem complex. The presence of hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated liver injury. In contrast, the associated co-morbidities like diabetes mellitus or obesity may increase the risk of developing adverse liver outcomes. These findings implicate that components of MAFLD may have diverse effects on the clinical manifestations of CHB. To this end, a clinical strategy is proposed for managing patients with concurrent CHB and MAFLD. This review article discusses the updated evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming at optimizing holistic health care in the CHB population.

Citations

Citations to this article as recorded by

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B
Maria Kalafateli, Roberta Forlano, Eleanor Barnes, Laura Martinez-Gili, Madeleine Lacey, Giordano Sigon, Benjamin H. Mullish, Vincent Mallet, Lucia Parlati, Paul Richardson, Niamh Forde, Gaetano Serviddio, Rosanna Villani, Sabela Lens, Maria Buti, Elena V
Clinical Gastroenterology and Hepatology.2026; 24(3): 701.     CrossRef
Triglyceride-based lipotoxicity in the pathophysiology of chronic diseases
Junjun Liu, Xiude Fan, Yongfeng Song, Jiajun Zhao
Trends in Endocrinology & Metabolism.2026; 37(4): 371.     CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Shang-Chin Huang, Jia-Horng Kao
Clinical and Molecular Hepatology.2026; 32(1): 423.     CrossRef
The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu
Frontiers in Immunology.2026;[Epub]     CrossRef
Association between fatty liver and risk of liver failure in patients with acute hepatitis B: a retrospective cohort study
Xiao-hao Wang, Yu-nan Chang, Lu Zhang, Yan-li Yang, Lu-wen Liang, Yi Zeng, Zhi Zhou, Shan Zhong, Hu Li
Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
Viral hepatitis and liver disease in the Mongolian community in London ('MoLo'): A mixed methods study protocol to investigate the epidemiology and burden of disease to inform clinical and public health interventions
Emily Martyn, Nara Dashdorj, Jessica Carter, Indrajit Ghosh, Enkh-Oyun Amarbayasgalan, Khadija Said Mohammed, Elizabeth Waddilove, Marion Delphin, Kathryn Jack, Camila Picchio, Joy Ko, Michelle Berkeley, Rubin Rose-Key, Eleni Nastouli, Sema Mandal, Monica
Wellcome Open Research.2026; 11: 72.     CrossRef
Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease
Wencong Li, Shiheng Liu, Weiguang Ren, Xiaoxiao Zhang, Lingdi Liu, Fang Han, Ying Zhang, Yuemin Nan, Suxian Zhao
Frontiers in Medicine.2026;[Epub]     CrossRef
Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita
Diabetic Medicine.2026;[Epub]     CrossRef
Hepatitis B virus exposure and metabolic dysfunction-associated steatotic liver disease in U.S. adults: A nationally representative analysis from NHANES 2017-2020
Youping Lin, Yanjuan Song, Qiuming Lin, Minran Li
The American Journal of the Medical Sciences.2026;[Epub]     CrossRef
Nomogram integrating serological markers and clinical parameters for predicting severe hepatic steatosis in patients with abnormal glucose metabolism
Ping Hu, Ao Zhong, Yuting Shen, Yinchen Yuan, Qing Jin, Quan Chen
Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
Steatosis Paradox: Unraveling Pathways of Suppressive Effect of Hepatic Steatosis on Hepatitis B Virus
Shang-Chin Huang, Jia-Horng Kao
Biomedical Journal.2026; : 100969.     CrossRef
Periodontitis and Chronic Liver Disease: Mechanistic Insights Focusing on Porphyromonas gingivalis—A Narrative Review
Yue Ying, Yuwei Nie, Jiahui Zhao, Qin Dong, Meixian Chen, Aijia Jiang, Nan Liu, Tong Xu, Junchao Liu, Yaping Pan, Li Lin, Dongmei Zhang
Microorganisms.2026; 14(4): 736.     CrossRef
Predicting the highly imbalanced hepatitis B virus infection outcome in Chinese middle-aged and older adults using an ensemble machine learning approach
Chen Sun, Xiaohan Yi, Nyi Nyi Soe, Phyu Mon Latt, Biying Wang, Zhongqun Zhao, Zhen Yu, Xianglong Xu
Discover Public Health.2026;[Epub]     CrossRef
The stealthy saboteur: hepatic steatosis and its erosion of APRI and FIB-4 accuracy
Huaying Zhou, Yuhong Li, Maoping Li, Jing Ma
Frontiers in Medicine.2026;[Epub]     CrossRef
Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes
Qin Lou, Jiarong Cai, Jianhua Yin
Microorganisms.2026; 14(4): 853.     CrossRef
Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B
Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
American Journal of Gastroenterology.2025; 120(2): 401.     CrossRef
Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29‐year follow‐up
Ming‐Whei Yu, Wan‐Jung Wu, Chih‐Lin Lin, Chun‐Jen Liu, Wei‐Ya Peng, Pin‐Yu Huang, Yi‐Wen Huang, Jui‐Ting Hu, Hung‐Chuen Chang, Jyh‐Ming Liou
Hepatology Research.2025; 55(1): 46.     CrossRef
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
Journal of Hepatology.2025; 83(1): 43.     CrossRef
Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction
Ammara A Majeed, Amna S Butt
World Journal of Hepatology.2025;[Epub]     CrossRef
Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis
Qingyan Kong, Diao Kong, Bei Li, Wei Peng, Zheyu Chen
Academic Radiology.2025; 32(11): 6514.     CrossRef
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2025; 31(1): 261.     CrossRef
Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China
Di Shen, Xintian Cai, Junli Hu, Shuaiwei Song, Qing Zhu, Huimin Ma, Yingying Zhang, Rui Ma, Pan Zhou, Wenbo Yang, Jing Hong, Delian Zhang, Nanfang Li
Journal of Inflammation Research.2025; Volume 18: 1623.     CrossRef
Divergent roles of MASLD components in chronic hepatitis B: A double-edged sword
Shang-Chin Huang, Tung-Hung Su
Journal of Hepatology.2025; 83(1): e34.     CrossRef
Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
Toru Nakamura, Atsutaka Masuda, Dan Nakano, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi
Cells.2025; 14(6): 428.     CrossRef
Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection
Chih-Jan Ko
American Journal of Cancer Research.2025; 15(2): 737.     CrossRef
Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clinical and Molecular Hepatology.2025; 31(Suppl): S182.     CrossRef
SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B
Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao
The Journal of Infectious Diseases.2025; 232(2): 474.     CrossRef
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Hepatology International.2025; 19(4): 959.     CrossRef
Non-invasive Assessment of Advanced Fibrosis and Steatosis in Chronic Hepatitis B Patients with Comorbid NAFLD
Zhenhua Zhou, Feng Chen, Rongrong Zou, Qianhui Li, Xiaomin Xu
Hepatitis Monthly.2025;[Epub]     CrossRef
Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning
Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng
Journal of Imaging Informatics in Medicine.2025; 38(6): 4349.     CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
Health Science Reports.2025;[Epub]     CrossRef
Molecular mechanisms of pyroptosis in non-alcoholic steatohepatitis and feasible diagnosis and treatment strategies
Dong-fang Shang, Wen-qian Xu, Qing Zhao, Chen-lu Zhao, Si-ying Wang, Yong-li Han, He-guo Li, Ming-hao Liu, Wen-xia Zhao
Pharmacological Research.2025; 216: 107754.     CrossRef
Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine
Yaru Shi, Rong Fan
Interdisciplinary Medicine.2025;[Epub]     CrossRef
The Associations of Serum Folate Forms with Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Fibrosis: A Nationwide Cross-Sectional Study
Hai Zhao, Wei Fan, Yan Yan, Yuxing Liu, Xuejun Kang
Metabolites.2025; 15(6): 370.     CrossRef
Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya
Preventive Medicine: Research & Reviews.2025; 2(4): 183.     CrossRef
Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens
Mei Huang, Dongyao Wang, Jiao Huang, An-Na Bae, Yun Xia, Xutu Zhao, Mahsa Mortaja, Marjan Azin, Michael R. Collier, Yevgeniy R. Semenov, Jong Ho Park, Shadmehr Demehri
Nature Communications.2025;[Epub]     CrossRef
Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease
Hualing Wang, Xinyu Liu, Chunyi Wang, Shishuang Yu, Xiuli Yang, Xiyu Cao, Maocai Luo, Shiwei Liu, Chuantao Zhang
Frontiers in Pharmacology.2025;[Epub]     CrossRef
Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis
Won-Mook Choi, Wai-Kay Seto
Hepatology.2025;[Epub]     CrossRef
The Role of Chinese Medicine in the Treatment of Chronic Hepatitis B
Shihao Zheng, Qiuyue Wang, Wenying Qi, Jinchi Xie, Xiaobin Zao, Xiaoke Li, Peng Zhang, Yongan Ye
The American Journal of Chinese Medicine.2025; 53(05): 1285.     CrossRef
Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B
Tyng‐Yuan Jang, Chih‐Wen Wang, Po‐Cheng Liang, Yu‐Ju Wei, Ming‐Lun Yeh, Yi‐Hung Lin, Chao‐Kuan Huang, Pei‐Chien Tsai, Yu‐Min Ko, Yi‐Shan Tsai, Kuan‐Yu Chen, Ching‐Chih Lin, Zu‐Yau Lin, Jee‐Fu Huang, Chia‐Yen Dai, Chung‐Feng Huang, Wan‐Long Chuang, Ming‐Lu
Journal of Gastroenterology and Hepatology.2025; 40(9): 2290.     CrossRef
Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007–2020
Zhounan Wu, Yuhang Liang, Li Zeng, Jiayi Fang, Jinshen He
Journal of Health, Population and Nutrition.2025;[Epub]     CrossRef
HBV and host metabolic crosstalk: Reprogramming pathways for viral replication and pathogenesis
YanYing Yan, Zhiqiang Wei, Min Zheng, Mengji Lu, Xueyu Wang
Virologica Sinica.2025; 40(5): 685.     CrossRef
Predictive Value of Hepatic Steatosis for Postoperative Recurrence in Hepatitis B-Related Hepatocellular Carcinoma: Development of a Machine Learning-Based Prognostic Model
Aoyun Hao, Changlei Li, Ruitao Sun, Bin Tan, Guanming Shao, Kun Li, Na Li, Weiyu Hu, Chao Qu, Jingyu Cao
Journal of Hepatocellular Carcinoma.2025; Volume 12: 2459.     CrossRef
Identification and Validation of Lipid Metabolism-Related Biomarkers GPD1 and CEBPD in Metabolic Dysfunction-Associated Steatohepatitis
Jianyu Zhou, Chunying Xiao, Bin Huang, Fenfang Chen
Journal of Inflammation Research.2025; Volume 18: 14805.     CrossRef
Knowledge, attitudes, and practices toward fatty liver disease in patients with hepatitis B combined fatty liver disease
Qian Li, Yongping Qiu, Lang Xiao, Lijian Ran, Hongli Deng, Xin Lu, Shilian Li, Yan Guo, Maolan Fu, Xuqing Zhang, Jie Xia, Huimin Liu
Scientific Reports.2025;[Epub]     CrossRef
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma
Subhrojyoti Mukherjee, Manish Kumar
Expert Review of Anticancer Therapy.2025; : 1.     CrossRef
Effects of Non-Alcoholic Fatty Liver Disease on Baseline Histology and 96-Week Entecavir Response in Treatment-Naïve Chronic Hepatitis B
Xiaohui Gu, Weiguang Yang, Yue Hu, Yixin Li, Liwei Zheng, Bei Jiang
Infection and Drug Resistance.2025; Volume 18: 6817.     CrossRef
Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study
Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
Cancers.2025; 18(1): 120.     CrossRef
Usefulness of the Fibrosis‐4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients
Jun Inoue, Takehiro Akahane, Tomoo Kobayashi, Osamu Kimura, Kosuke Sato, Masashi Ninomiya, Tomoaki Iwata, Satoshi Takai, Norihiro Kisara, Toshihiro Sato, Futoshi Nagasaki, Masahito Miura, Takuya Nakamura, Teruyuki Umetsu, Akitoshi Sano, Mio Tsuruoka, Masa
Hepatology Research.2024; 54(2): 131.     CrossRef
The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
Shang‐Chin Huang, Jia‐Horng Kao
The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6.     CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion
Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Chen-Hua Liu, Sih-Han Liao, Chun-Ming Hong, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Clinical Gastroenterology and Hepatology.2024; 22(3): 581.     CrossRef
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
Sung Won Lee, Daniel Q. Huang, Ricki Bettencourt, Veeral Ajmera, Monica Tincopa, Nabil Noureddin, Maral Amangurbanova, Harris Siddiqi, Egbert Madamba, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Masato Yoneda, Ramzan I
Alimentary Pharmacology & Therapeutics.2024; 59(1): 80.     CrossRef
Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison
Zheng Lin, Yue-yi Shi, Lu-yan Yu, Chen-xi Ma, Si-yi Pan, Yuan Dou, Qiu-jun Zhou, Yi Cao
Frontiers in Medicine.2024;[Epub]     CrossRef
The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu
Journal of Gastroenterology and Hepatology.2024; 39(1): 193.     CrossRef
High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare
Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng
BMC Public Health.2024;[Epub]     CrossRef
Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC
Mei-Hsuan Lee, Yi-Ting Chen, Yu-Han Huang, Sheng-Nan Lu, Tsai-Hsuan Yang, Jee-Fu Huang, Szu-Ching Yin, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, Hwai-I Yang, Hsuan-Yu Chen, Chien-Jen Chen
Clinical Gastroenterology and Hepatology.2024; 22(6): 1275.     CrossRef
Reply
Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao
Clinical Gastroenterology and Hepatology.2024; 22(9): 1957.     CrossRef
Current perspectives of viral hepatitis
Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma
Xin Cai, Shi Peng, Xuan Xiao, Zhaoyang Huang, Pingan Zhang
Scientific Reports.2024;[Epub]     CrossRef
The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
María Hernández‐Pérez, Daniel Riado, Eva Pena, Carmen Méndez, Fernando Pinedo, Paloma Ramos, Pilar Castillo, Miriam Romero, Conrado Fernández‐Rodríguez, Antonio Olveira
Alimentary Pharmacology & Therapeutics.2024; 60(5): 613.     CrossRef
Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load
Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai
Journal of Gastroenterology and Hepatology.2024; 39(11): 2327.     CrossRef
Response to the letter of HEPI-D-24–00252
Shang-Chin Huang, Tung-Hung Su, Jia-Horng Kao
Hepatology International.2024; 18(4): 1340.     CrossRef
Functional cure of chronic hepatitis B encounters resmetirom
Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng
Clinical and Molecular Hepatology.2024; 30(3): 580.     CrossRef
Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation
Jun Wang, Hongzhou Lu, Qian Li
Frontiers in Immunology.2024;[Epub]     CrossRef
Outcome of bariatric surgery in patients with unexpected liver cirrhosis: A multicenter study from China
Xia Sun, Libin Yao, Xing Kang, Weihua Yu, Fidele Kakule Kitaghenda, Mohammad Sajjad Ibn Rashid, Angeline Nogue Taguemkam, Jian Hong, Zhiyong Dong, Xitai Sun, Xiaocheng Zhu
Liver Research.2024; 8(3): 172.     CrossRef
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
Lung-Yi Mak
Journal of Liver Cancer.2024; 24(2): 145.     CrossRef
Comparison of Non-invasive Biochemical Fibrosis Markers According to Obesity-Based Metabolic Profile in Chronic Liver Disease with Chronic Hepatitis B Etiology
Sedat Çiftel
Ağrı Tıp Fakültesi Dergisi.2024; 2(3): 113.     CrossRef
Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa
Kaimin Song, Lan Ren, Yunyun Qian, Huitong Wang, Zhixiang Guo, Huatang Zhang, Yijie Lin, Yijuan Zheng, Dawu Zeng, Yongjun Zhou, Zhijun Su, Xueping Yu
BMC Infectious Diseases.2024;[Epub]     CrossRef
Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B
Qingyan Kong, Qianqian Gao, Wenjie Li, Zheyu Chen
Asian Journal of Surgery.2024; 47(11): 4725.     CrossRef
Retrospective cohort evaluation study in terms of cardiovascular and metabolic diseases in chronic hepatitis B patients
Aysun Yakut
Frontiers in Endocrinology.2024;[Epub]     CrossRef
An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review
Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Sirshendu Chaudhuri, Saibal Das
Hospital Practice.2024; 52(4-5): 123.     CrossRef
Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B
Cao-Ngoc Huynh
American Journal of Cancer Research.2024; 14(9): 4567.     CrossRef
Obesity and risk for liver disease: a two-sample Mendelian randomisation study
Wen An, Jing Luo, Zhe Yu, Mengqi Li, Herui Wei, Aqian Song, Yuanpeng Mao, Hao Bian, Lingling He, Fan Xiao, Hongshan Wei
British Journal of Nutrition.2024; 132(10): 1403.     CrossRef
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao
Scientific Reports.2024;[Epub]     CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future
Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
World Journal of Hepatology.2024; 16(12): 1365.     CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371.     CrossRef
Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B
Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Hepatology International.2023; 17(5): 1139.     CrossRef
Reply to: ‘A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?’
Hyun Yang, Ji Hoon Kim, Ji Won Han, Soon Kyu Lee, Jeong Won Jang
Journal of Hepatology.2023; 79(4): e155.     CrossRef
Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Xuehong Zhang, Sang Hoon Ahn
International Journal of Cancer.2023; 153(8): 1448.     CrossRef

17,861 View

578 Download

74 Web of Science

Crossref

Letter to the Editor

Viral hepatitis

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol 2023;29(2):510-512.
Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

PDF

Citations

Citations to this article as recorded by

Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Jeong-Ju Yoo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 513.     CrossRef

6,785 View

79 Download

1 Web of Science

Crossref

Original Article

Viral hepatitis

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol 2023;29(2):482-495.
Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

Abstract

PDF
Supplementary Material

Background/Aims
The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy.
Methods
Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed.
Results
Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase.
Conclusions
A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.

Citations

Citations to this article as recorded by

Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients
Tai-Chung Tseng, Tetsuya Hosaka, Mei-Hung Pan, Chun-Jen Liu, Fumitaka Suzuki, Chien-Jen Chen, Tung-Hung Su, Hiromitsu Kumada, Wan-Ting Yang, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Hwai-I. Yang, Jia-Horng Kao
Hepatology.2026; 83(1): 142.     CrossRef
Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log10 IU/mL)
Guifeng Li, Rong Ren, Jie Liu, Jia Li
Journal of Clinical Medicine.2026; 15(6): 2164.     CrossRef
Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance
Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
Journal of Gastroenterology and Hepatology.2025; 40(7): 1675.     CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
Health Science Reports.2025;[Epub]     CrossRef
Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B
Suk‐Chan Jang, Won‐Mook Choi, Gi‐Ae Kim, Gwang Hyeon Choi, Yun Bin Lee, Dong Hyun Sinn, Hye‐Lin Kim, Young‐Suk Lim
Liver International.2025;[Epub]     CrossRef
Comparison of the efficacy and action mechanism of Chinese patent medicines for liver fibrosis and cirrhosis
Lingping Fu, Jin Xie, ZeXin Wang, Tao Jiang, Yi Zeng, Jing Yan, Rong Sun, Mengshuang Huang, Shengyi Du, Xiaobao Wang, Yuyang Liu, Kailai Xi, Ailin Chen, Xiao Ma, Jinhao Zeng, Thomas Efferth
Phytomedicine.2025; 148: 157246.     CrossRef
Longitudinal observation of chronic domestic cat hepadnavirus infection in cats with evidence of extrahepatic involvement
Sabrina Wahyu Wardhani, Sitthichok Lacharoje, Tanit Kasantikul, Chutchai Piewbang, Somporn Techangamsuwan
Journal of Feline Medicine and Surgery.2025;[Epub]     CrossRef
Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?
Yen-Chun Liu, Wen-Juei Jeng
Current Hepatology Reports.2024; 23(1): 11.     CrossRef
Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation
Jinglin Tang, Jiaxuan Zhang, Gaoli Zhang, Wenhui Peng, Ning Ling, Yingzhi Zhou, Hongmei Xu, Hong Ren, Min Chen, Marthandan Mahalingam, Swati Jain
mBio.2024;[Epub]     CrossRef
Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable?
Shasha Ma, Lian Zhou, Shutao Lin, Mingna Li, Jing Luo, Lubiao Chen
Diagnostics.2024; 14(5): 456.     CrossRef
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis
Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim
JHEP Reports.2024; 6(7): 101089.     CrossRef
Inverse relationship between HBV DNA levels and liver histopathological changes in immune‐tolerant CHB patients
Deliang Huang, Huiyi Lai, Zhibin Zhu, Hong Yu, Jinghan Peng, Yuanyuan Chen, Xuejiao Liao, Jun Chen
Journal of Viral Hepatitis.2024; 31(7): 363.     CrossRef
Editorial: High qHBsAg—is it a good or bad signal?
Beom Kyung Kim
Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616.     CrossRef
Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase
Jian Wang, Li Zhu, Zhiyi Zhang, Shaoqiu Zhang, Yifan Pan, Yuanyuan Li, Fei Cao, Chao Jiang, Tao Fan, Ye Xiong, Jiacheng Liu, Yuxin Chen, Shengxia Yin, Xin Tong, Chuanwu Zhu, Xingxiang Liu, Jie Li, Chao Wu, Rui Huang
Virology Journal.2024;[Epub]     CrossRef
Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis
Min Liu, Taixue Zhao, Jinyang Zhang, Bing Bu, Ruyi Zhang, Xueshan Xia, Jiawei Geng
Reviews in Medical Virology.2024;[Epub]     CrossRef
Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT
Menghui Duan, Huanming Xiao, Meijie Shi, Yubao Xie, Pengtao Zhao, Sheng Li, Xiaoling Chi, Xueen Liu, Hui Zhuang
BMC Infectious Diseases.2024;[Epub]     CrossRef
Preface
Seung Up Kim
Clinical and Molecular Hepatology.2024; 30(Suppl): S3.     CrossRef
Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis
Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
Clinical and Molecular Hepatology.2024; 30(Suppl): S106.     CrossRef
HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis
Yuanyuan Li, Yijia Zhu, Dongmei Gao, Yifan Pan, Jian Wang, Shaoqiu Zhang, Xiaomin Yan, Li Zhu, Chuanwu Zhu, Xingxiang Liu, Zhaoping Zhang, Jie Li, Yuxin Chen, Rui Huang, Chao Wu
Virology Journal.2024;[Epub]     CrossRef
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
Joo Hyun Oh, Dong Hyun Sinn
Clinical and Molecular Hepatology.2023; 29(2): 367.     CrossRef
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Chia-Ming Chu, Yun-Fan Liaw
Clinical and Molecular Hepatology.2023; 29(2): 510.     CrossRef
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
Moon Haeng Hur, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2023; 29(2): 363.     CrossRef
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Jeong-Ju Yoo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 513.     CrossRef
Research Progress in Histological Features and Related Influencing Factors of Chronic Hepatitis B Patients with Persistent Normal ALT
宇行刘
Advances in Clinical Medicine.2023; 13(05): 8702.     CrossRef
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clinical and Molecular Hepatology.2023; 29(3): 779.     CrossRef
HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
Soon Kyu Lee, Jung Hyun Kwon
Clinical and Molecular Hepatology.2023; 29(3): 825.     CrossRef

8,683 View

236 Download

24 Web of Science

Crossref

Editorials

Viral hepatitis

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol 2023;29(1):118-119.
Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0413

PDF

Citations

Citations to this article as recorded by

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka
Alimentary Pharmacology & Therapeutics.2026; 63(8): 1089.     CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
Health Science Reports.2025;[Epub]     CrossRef
Gray zone and the need for expansion in chronic hepatitis B: From theory to clinical practice
Thang Viet Luong, Ngoc Phan Hong Nguyen, Tri Van Nguyen, Duong Hung Tran, Thien Dinh Nguyen, Hai Nguyen Ngoc Dang
World Journal of Hepatology.2025;[Epub]     CrossRef
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon
Clinical and Molecular Hepatology.2024; 30(3): 500.     CrossRef
The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(2): 263.     CrossRef
Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Xuehong Zhang, Sang Hoon Ahn
International Journal of Cancer.2023; 153(8): 1448.     CrossRef

7,567 View

208 Download

8 Web of Science

Crossref

Viral hepatitis

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol 2023;29(1):113-117.
Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0333

PDF

Citations

Citations to this article as recorded by

Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance
Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
Journal of Gastroenterology and Hepatology.2025; 40(7): 1675.     CrossRef
Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B”
Soon Kyu Lee
The Korean Journal of Gastroenterology.2025; 85(3): 245.     CrossRef
Hepatocellular carcinoma surveillance after HBsAg seroclearance
Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Exploration of Digestive Diseases.2024; : 175.     CrossRef
Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure
Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Victor Pântea, Gheorge Placinta, Scott J. Cotler, Andrew Vaillant, Harel Dahari
Hepatology Communications.2023;[Epub]     CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 191.     CrossRef
Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus
Daniel G. Sausen, Oren Shechter, William Bietsch, Zhenzhen Shi, Samantha M. Miller, Elisa S. Gallo, Harel Dahari, Ronen Borenstein
International Journal of Molecular Sciences.2022; 23(24): 15973.     CrossRef

7,072 View

123 Download

5 Web of Science

Crossref

Original Article

Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus

Daxian Wu, Qunfang Rao, Zhongyang Xie, Xiaoqing Zhu, Yuanmei Che, Jian Wu, Hainv Gao, Jingyu Zhang, Zhouhua Hou, Xiaoyu Cheng, Zeyu Sun

Clin Mol Hepatol 2022;28(4):912-925.
Published online July 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0121

Abstract

PDF
Supplementary Material

Background/Aims
Acute-on-chronic liver failure (ACLF) is a catastrophic illness. Few studies investigated the prognostic value of vitamin D-binding protein (VDBP) for hepatitis B virus (HBV)-related ACLF (HBV-ACLF) resulted in conflicting results.
Methods
Two prospective HBV-ACLF cohorts (n=287 and n=119) were enrolled to assess and validate the prognostic performance of VDBP.
Results
VDBP levels in the non-survivors were significantly lower than in the survivors (P<0.001). Multivariate Cox regression demonstrated that VDBP was an independent prognostic factor for HBV-ACLF. The VDBP level at admission gradually decreased as the number of failed organs increased (P<0.001), and it was closely related to coagulation failure. The areas under the receiver operating characteristic curve (AUCs) of the Child-Pugh-VDBP and chronic liver failuresequential organ failure assessment (CLIF–SOFA)-VDBP scores were significantly higher than those of Child-Pugh (P<0.001) and CLIF-SOFA (P=0.0013). The AUCs of model for end-stage liver disease (MELD)-VDBP were significantly higher than those of MELD (P= 0.0384) only in the case of cirrhotic HBV-ACLF patients. Similar results were validated using an external multicenter HBV-ACLF cohort. By longitudinal observation, the VDBP levels gradually increased in survivors (P=0.026) and gradually decreased in non-survivors (P<0.001). Additionally, the VDBP levels were found to be significantly decreased in the deterioration group (P=0.012) and tended to be decreased in the fluctuation group (P=0.055). In contrast, they showed a significant increase in the improvement group (P=0.036).
Conclusions
The VDBP was a promising prognostic biomarker for HBV-ACLF. Sequential measurement of circulating VDBP shows value for the monitoring of ACLF progression.

Citations

Citations to this article as recorded by

Omics in acute‐on‐chronic liver failure
Peng Li, Xi Liang, Jinjin Luo, Jun Li
Liver International.2025;[Epub]     CrossRef
Deficiency of vitamin D-binding protein exacerbates liver fibrosis by disrupting iron homeostasis via the activation of YAP signaling
Qing Zheng, Qingquan Tan, Dan Wang, Yanling Ma, Yanni Zhou, Yonghua Chen, Dan Long, Jiayin Yang, Li Feng
Experimental Cell Research.2025; 452(2): 114767.     CrossRef
miR-223-3p predicts prognosis of hepatitis B virus-related acute-on-chronic liver failure and is involved in hepatocyte injury via HSP90B1
Feiyue Xie, Qiuping Ren, Jun He, Menghang Wu
Hereditas.2025;[Epub]     CrossRef

8,632 View

167 Download

3 Web of Science

Crossref

Review

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol 2022;28(3):408-424.
Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

Abstract

PDF

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2–2.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported. ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb/III trials are keenly anticipated.

Citations

Citations to this article as recorded by

Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure
Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen
Gut.2026; 75(1): 119.     CrossRef
Individualising endpoints in chronic HBV treatment: HBsAg loss and beyond
Milan J. Sonneveld, Harry L.A. Janssen
Journal of Hepatology.2026; 84(4): 823.     CrossRef
Update on combination therapies against HBV in clinical investigations
Lung-Yi Mak, Anna SF. Lok
Antiviral Research.2026; 245: 106321.     CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure
Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Clinical and Molecular Hepatology.2026; 32(1): 184.     CrossRef
Direct Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies
Simone La Frazia, Alessia Magnapera, Lorenzo Piermatteo, Stefano D’Anna, Leonardo Duca, Valentina Svicher, Romina Salpini
Viruses.2026; 18(2): 185.     CrossRef
RNA nanomedicine in liver diseases
Anita Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat
Hepatology.2025; 81(6): 1847.     CrossRef
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
Lung Yi Mak, Christine I Wooddell, Oliver Lenz, Thomas Schluep, James Hamilton, Heather L Davis, Xianhua Mao, Wai-Kay Seto, Michael Biermer, Man-Fung Yuen
Gut.2025; 74(3): 440.     CrossRef
Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA
Jihua Ren, Shengtao Cheng, Fang Ren, Huiying Gu, Daiqing Wu, Xinyan Yao, Ming Tan, Ailong Huang, Juan Chen
Genes & Diseases.2025; 12(1): 101215.     CrossRef
Investigational RNA Interference Agents for Hepatitis B
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
BioDrugs.2025; 39(1): 21.     CrossRef
Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy”
Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Journal of Hepatology.2025; 82(5): e228.     CrossRef
Inhibition of Hepatitis B Virus Replication by a Novel GalNAc–siRNA In Vivo and In Vitro
Zhipeng Zhang, Yanqin Ma, Yan He, Dong Wang, Kun Yue, Xiaomei Zhang, Huaien Song
ACS Omega.2025; 10(1): 484.     CrossRef
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Zhen-Xin Qin, Ling Zuo, Ziran Zeng, Rongguan Ma, Wenyan Xie, Xiao Zhu, Xiaorong Zhou
Expert Opinion on Drug Delivery.2025; 22(4): 455.     CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Hepatology International.2025; 19(2): 304.     CrossRef
Prospect of emerging treatments for hepatitis B virus functional cure
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2025; 31(Suppl): S165.     CrossRef
Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0
Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech,
Clinical and Molecular Hepatology.2025; 31(Suppl): S134.     CrossRef
CTLA4 modulates B cell receptor signals to inhibit HBsAb secretion in chronic hepatitis B patients
Shengxia Yin, Minxin Mao, Linyan Gong, Yijia Zhu, Yawen Wan, Xin Tong, Jian Wang, Guiyang Wang, Yong Liu, Chao Wu, Rui Huang, Yuxin Chen
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(6): 167848.     CrossRef
Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine
Yaru Shi, Rong Fan
Interdisciplinary Medicine.2025;[Epub]     CrossRef
Advances in the management of hepatitis B
Ruma Rajbhandari, Vy H Nguyen, Abigail Knoble, Gregory Fricker, Raymond T Chung
BMJ.2025; 389: e079579.     CrossRef
Residual viral expression in siRNA-treated HBV-replicating cell and mouse models
Mingzhu Xu, Yuyan Qian, Ziyang Song, Haiyu Wang, Lei Yue, Jiangxia Liu, Yaming Li, Wenjing Zai, Zhenghong Yuan, Jieliang Chen
Antiviral Research.2025; 240: 106210.     CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Hepatology International.2025; 19(4): 704.     CrossRef
Targeting HBV with RNA interference: Paths to cure
Matteo Iannacone, Cristian G. Beccaria, Lena Allweiss, Julie Lucifora, John E. Tavis, Adam J. Gehring, Maura Dandri
Science Translational Medicine.2025;[Epub]     CrossRef
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure
Ana Verma, Raymond T. Chung
Current Opinion in HIV and AIDS.2025; 20(5): 449.     CrossRef
Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and Chimpanzees
Christine I. Wooddell, Lung Yi Mak, Wai-Kay Seto, Bruce D. Given, Man-Fung Yuen
Microorganisms.2025; 13(8): 1787.     CrossRef
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D
Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang
Virology Journal.2025;[Epub]     CrossRef
Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B
Lu Zhang, Yu Cao, Sijing Zhuang, Jingjing Sun, Qiao Tong, Jianjun Xi, Shourong Liu, Rangxiao Zhuang
Frontiers in Pharmacology.2025;[Epub]     CrossRef
Functional cure for chronic hepatitis B: A state of immune control over cccDNA persistence
Kunyu Zhao, Lili Wu, Yu Wu, Qianqian Jiang, Mengmeng Zhu, Suzhen Jiang, Chao Zhang, Fengmin Lu
Infectious Diseases & Immunity.2025;[Epub]     CrossRef
Hepatitis B functional cure: Current and future perspective
Sudheer Marrapu, Jinit R Soni, Kislaya Kamal, Ramesh Kumar
World Journal of Hepatology.2025;[Epub]     CrossRef
Strategies to Achieve Functional Cure in HBV: Focus on siRNA
Eyyel Karthikeyan, Robert G. Gish
Current Hepatology Reports.2025;[Epub]     CrossRef
In-Silico Development of Effective Short Hairpin RNA Molecules Targeting the Transactivator Region of Human Hepatitis B Virus
Amir Pouremamali, Mehrdad Ravanshad, Leila Asadi Samani, Farhad Pouremamali, Reza Ghanbari
Jundishapur Journal of Microbiology.2025;[Epub]     CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
Hepatoma Research.2025;[Epub]     CrossRef
Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy
Xiao‐Tong Li, Shu‐Yi Peng, Shao‐Mei Feng, Ting‐Yu Bao, Sheng‐Zhang Li, Shi‐Ying Li
Small.2024;[Epub]     CrossRef
Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics
Jie-Li Hu, Ai-Long Huang
Virologica Sinica.2024; 39(1): 9.     CrossRef
Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo
Elena M. Smekalova, Maria G. Martinez, Emmanuel Combe, Anuj Kumar, Selam Dejene, Dominique Leboeuf, Chao-Ying Chen, J. Robert Dorkin, Lan Shuan Shuang, Sarah Kieft, Lauren Young, Luis Alberto Barrera, Michael S. Packer, Giuseppe Ciaramella, Barbara Teston
Molecular Therapy Nucleic Acids.2024; 35(1): 102112.     CrossRef
Can Radionuclide Therapy be the Solution for Hepatitis B Virus Infection?
Pil Soo Sung, Ie Ryung Yoo
Nuclear Medicine and Molecular Imaging.2024; 58(5): 255.     CrossRef
Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161
Angela M. Lam, Ravi R. Dugyala, Muhammed Sheraz, Fei Liu, Emily P. Thi, Ingrid E. Graves, Andrea Cuconati, Holly Micolochick Steuer, Andrzej Ardzinski, Nathan Overholt, Jeremy D. Mason, Dimitar Gotchev, Andrew G. Cole, Troy O. Harasym, Michael J. Sofia
Viruses.2024; 16(3): 323.     CrossRef
Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model
Ellen Van Gulck, Nádia Conceição-Neto, Liese Aerts, Wim Pierson, Lore Verschueren, Mara Vleeschouwer, Vinod Krishna, Isabel Nájera, Frederik Pauwels
Viruses.2024; 16(3): 347.     CrossRef
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies
Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang
World Journal of Gastroenterology.2024; 30(10): 1295.     CrossRef
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873
Darryl Kato, Regina Wai-Yan Choy, Eda Canales, Ryan A. Dick, April D. Lake, Nathan D. Shapiro, Elbert Chin, Jiayao Li, Jennifer R. Zhang, Qiaoyin Wu, Roland D. Saito, Sammy Metobo, Evangelos Aktoudianakis, Scott D. Schroeder, Zheng-Yu Yang, Dylan M. Glatt
ACS Medicinal Chemistry Letters.2024; 15(4): 546.     CrossRef
Model‐based meta‐analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B‐infected mice
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan‐Jose Perez‐Ruixo
CPT: Pharmacometrics & Systems Pharmacology.2024; 13(5): 729.     CrossRef
Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents
Robert Lam, Joseph K Lim
World Journal of Hepatology.2024; 16(3): 331.     CrossRef
Prospects for Controlling Hepatitis B Globally
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza
Pathogens.2024; 13(4): 291.     CrossRef
Therapeutic advances in HBV cure
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clinical Liver Disease.2024;[Epub]     CrossRef
Genotyping Hepatitis B virus by Next-Generation Sequencing: Detection of Mixed Infections and Analysis of Sequence Conservation
Eva Dopico, Marta Vila, David Tabernero, Josep Gregori, Ariadna Rando-Segura, Beatriz Pacín-Ruíz, Laura Guerrero, Itziar Ubillos, Miguel J. Martínez, Josep Costa, Josep Quer, Javier Pérez-Garreta, Alejandra González-Sánchez, Andrés Antón, Tomás Pumarola,
International Journal of Molecular Sciences.2024; 25(10): 5481.     CrossRef
Analysis of the pharmacokinetics and efficacy of RBD1016 – A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model
Qian Li, Taohua Geng, Haiyan Li, Shuquan Zheng, Sara Svedlund, Liming Gan, Ann-Charlotte Egnell, Shan Gao, Rui Chen, Pei Hu
Heliyon.2024; 10(11): e31924.     CrossRef
Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection
Wenjing Zai, Min Yang, Kuan Jiang, Juan Guan, Huijing Wang, Kongying Hu, Chao Huang, Jieliang Chen, Wei Fu, Changyou Zhan, Zhenghong Yuan
Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library
Biplav Shrestha, Sisi Yang, Lauren Griffith, Julia Ma, Fuxuan Wang, Hui Liu, Qiong Zhao, Yanming Du, Jiming Zhang, Jinhong Chang, Ju-Tao Guo
Antiviral Research.2024; 228: 105955.     CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2024; 30(3): 539.     CrossRef
Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain
Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng
Viruses.2024; 16(7): 1151.     CrossRef
The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy
Mingming Zhang, Han Chen, Huan Liu, Hong Tang
Biomarker Research.2024;[Epub]     CrossRef
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo, Pisit Tangkijvanich, Won Young Tak, Vaidehi Thanawala, Daniel Cloutier, Shenghua Mao, Andre Arizpe, Andrea L Cathcart, Sneha V Gupta, Carey Hwang, Edward Gane
The Lancet Gastroenterology & Hepatology.2024; 9(12): 1121.     CrossRef
Novel NTCP ligand dimeric bile acid conjugated with ASO reduce hepatitis B virus surface antigen in vivo
Lei Lu, Dezi Cong, Tinghong Lv, Haisheng Wang, Xiaolei Wang
European Journal of Medicinal Chemistry.2024; 280: 116955.     CrossRef
Chitosan/siRNA nanoparticles targeting PARP-1 attenuate Neuroinflammation and apoptosis in hyperglycemia-induced oxidative stress in Neuro2a cells
Moqbel Ali Moqbel Redhwan, Hariprasad M.G., Suman Samaddar, Duaa Abdullah Bafail, Sumaia Abdulbari Ahmed Ali Hard, Sourav Guha
International Journal of Biological Macromolecules.2024; 282: 136964.     CrossRef
A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses
Mohadeseh Hasanpourghadi, Mikhail Novikov, Robert Ambrose, Arezki Chekaoui, Dakota Newman, ZhiQuan Xiang, Andrew D. Luber, Sue L. Currie, XiangYang Zhou, Hildegund C.J. Ertl
JCI Insight.2024;[Epub]     CrossRef
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates
Linh Nguyen, Tiep Tien Nguyen, Ju-Yeon Kim, Jee-Heon Jeong
Journal of Nanobiotechnology.2024;[Epub]     CrossRef
Utilizing Engineered Bacteria as “Cell Factories” In Vivo for Intracellular RNA-Loaded Outer Membrane Vesicles’ Self-Assembly in Tumor Treatment
Dawei Sun, Yize Li, Xiaoxuan Yin, Yali Fan, Jing Liu, Yaxin Wang, Xinyu Liu, Guijie Bai, Ke Li, Yanyan Shi, Peiyuan Liu, Yingying Zhang, Hanjie Wang
ACS Nano.2024; 18(52): 35296.     CrossRef
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants
Haiyan Li, Xiaoye Niu, Yu Zhang, Danning Zhang, Yanqing Zhang, Liqun Wang, Yongqing Miao, Yanxin Jiang, Jia Ji, Qiaoqiao Chen, Xiaoyun Wu, Emmanuel Njumbe Ediage, Thomas N. Kakuda, Michael Biermer
Clinical Pharmacology in Drug Development.2023; 12(2): 175.     CrossRef
Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow!
David Durantel
Antiviral Research.2023; 210: 105515.     CrossRef
New Approaches to Chronic Hepatitis B
Dan L. Longo, Geoffrey Dusheiko, Kosh Agarwal, Mala K. Maini
New England Journal of Medicine.2023; 388(1): 55.     CrossRef
The scientific basis of combination therapy for chronic hepatitis B functional cure
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim
Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 238.     CrossRef
Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review
Jie-Li Hu, Ai-Long Huang
Microorganisms.2023; 11(3): 600.     CrossRef
Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui
The Lancet Regional Health - Western Pacific.2023; 35: 100738.     CrossRef
The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang
Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung
Expert Review of Gastroenterology & Hepatology.2023; 17(5): 443.     CrossRef
Current and novel modalities for management of chronic hepatitis B infection
Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen, Hala M Raslan
World Journal of Hepatology.2023; 15(5): 585.     CrossRef
Past, present, and future of long-term treatment for hepatitis B virus
Teresa Broquetas, José A Carrión
World Journal of Gastroenterology.2023; 29(25): 3964.     CrossRef
Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers
Lung-Yi Mak, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen
Clinics in Liver Disease.2023; 27(4): 877.     CrossRef
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease
Pavel Strnad, Javier San Martin
Expert Opinion on Investigational Drugs.2023; 32(7): 571.     CrossRef
Chronic Hepatitis B Infection: New Approaches towards Cure
Mojisola Ogunnaike, Srijanee Das, Samiksha S. Raut, Ashrafi Sultana, Mohammad Ullah Nayan, Murali Ganesan, Benson J. Edagwa, Natalia A. Osna, Larisa Y. Poluektova
Biomolecules.2023; 13(8): 1208.     CrossRef
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen
Expert Opinion on Investigational Drugs.2023; 32(11): 971.     CrossRef
Cell-Penetrating Peptides as Vehicles for Delivery of Therapeutic Nucleic Acids. Mechanisms and Application in Medicine
Ekaterina D. Timotievich, Igor P. Shilovskiy, Musa R. Khaitov
Biochemistry (Moscow).2023; 88(11): 1800.     CrossRef
Gene-Editing and RNA Interference in Treating Hepatitis B: A Review
Nadiia Kasianchuk, Krystyna Dobrowolska, Sofiia Harkava, Andreea Bretcan, Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Robert Flisiak, Piotr Rzymski
Viruses.2023; 15(12): 2395.     CrossRef
Peptide carriers as delivery vehicles for therapeutic nucleic acids. Мechanisms and potential applications in medicine
E. D Timotievich, I. P Shilovskiy, M. R Khaitov
Биохимия.2023; 88(11): 2183.     CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials
Rex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Expert Opinion on Emerging Drugs.2022; 27(2): 127.     CrossRef
Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection
Ilaria Montali, Andrea Vecchi, Marzia Rossi, Camilla Tiezzi, Amalia Penna, Valentina Reverberi, Diletta Laccabue, Gabriele Missale, Carolina Boni, Paola Fisicaro
Biomedicines.2022; 10(6): 1224.     CrossRef
Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B
Mark A. Feitelson, Alla Arzumanyan, Ira Spector, Arvin Medhat
Biomedicines.2022; 10(9): 2210.     CrossRef
Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection
Rex Wan-Hin Hui, Lung-Yi Mak, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen
Current Hepatology Reports.2022; 21(4): 59.     CrossRef
State-of-the-art and emerging antivirals for chronic hepatitis B infection
Margarita Papatheodoridi, George V. Papatheodoridis
Expert Opinion on Pharmacotherapy.2022; 23(18): 1999.     CrossRef

17,971 View

755 Download

74 Web of Science

Crossref

Snapshot

Viral hepatitis

History and future of hepatitis B virus control in South Korea

Do Young Kim

Clin Mol Hepatol 2021;27(4):620-622.
Published online September 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0277

PDF

Citations

Citations to this article as recorded by

Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry
Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim
Journal of Liver Cancer.2025; 25(1): 109.     CrossRef
Trends in Prevalence of Obesity and Related Cardiometabolic and Renal Complications in Korea: A Nationwide Study 2007 to 2022
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jangho Lee, Yong-ho Lee
Journal of Obesity & Metabolic Syndrome.2025; 34(4): 414.     CrossRef
The Epidemiology of Hepatitis B Virus Infection in Korea: 15-Year Analysis
Log Young Kim, Jeong-Ju Yoo, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Dong Hyeon Lee, Jae Young Jang
Journal of Korean Medical Science.2024;[Epub]     CrossRef
Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B
Tae Hyung Kim, Ji Hoon Kim, Hyung Joon Yim, Yeon Seok Seo, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
Gut and Liver.2024; 18(2): 305.     CrossRef
Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell Lymphoma: Real-World Experience
Dae-Ho Choi, Sang Eun Yoon, Junhun Cho, Seok Jin Kim, Won Seog Kim
Acta Haematologica.2024; 147(6): 625.     CrossRef
Sex and ethnic disparities in hepatitis B evaluation and treatment across the world
Sahith Kudaravalli, Daniel Q. Huang, Ming-Lun Yeh, Lindsey Trinh, P.C. Tsai, Yao-Chun Hsu, Leslie Y. Kam, Vy H. Nguyen, Eiichi Ogawa, Dong Hyun Lee, Takanori Ito, Tsunamasa Watanabe, Masaru Enomoto, Carmen Monica Preda, Michael K.L. Ko, Rex Wan-Hin Hui, M
Journal of Hepatology.2024; 81(1): 33.     CrossRef
Association between Vitamin D Deficiency and Serologic Response to Hepatitis B Virus Vaccination among Heavy Industry Workers
Si-Ho Kim, Chang-Ho Chae
Vaccines.2024; 12(7): 723.     CrossRef
SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death
Jooyoung Lee, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Hye‐In An, Yong‐Jae Kwon, Hana Jin, Chan‐Gi Pack, Inki Kim, Young‐In Yoon, Gil‐Chun Park, Eun‐Kyoung Jwa, Jae Hyun Kwon, Jung‐Man Namgoong, Gi‐Won Song, Shin Hwang, Eunyoung Tak, Sung‐Gyu Lee
Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
Evaluation of the acute hepatitis B surveillance system in the Republic of Korea following the transition to mandatory surveillance
Jaehwa Chung, Jeonghee Yu, Myeongeun Cheon, Sangwoo Tak
Osong Public Health and Research Perspectives.2024; 15(4): 353.     CrossRef
Potential Association between Shift Work and Serologic Response to Hepatitis B Vaccination among Manufacturing Workers in Republic of Korea
Si-Ho Kim, Chang-Ho Chae
Vaccines.2024; 12(9): 1041.     CrossRef
Detection of hepatitis B virus genotypes in a group of hepatitis B virus-infected patients in central and northern Sri Lanka
T. T. Pattiyakumbura, K. G. K. Malkanthi, W. K. H. Dheerasekara, A. Manamperi, M. A. R. V. Muthugala
Access Microbiology .2024;[Epub]     CrossRef
Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study
Won Sohn, Yoosoo Chang, Yong Kyun Cho, Yun Soo Hong, Seungho Ryu
American Journal of Gastroenterology.2023; 118(1): 95.     CrossRef
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim
Hepatology Communications.2023; 7(2): e0011.     CrossRef
Estimated impact of the national hepatitis B immunization program on acute viral hepatitis B among adolescents in Republic of Korea
Chungman Chae, Sangwoo Tak
Osong Public Health and Research Perspectives.2023; 14(2): 138.     CrossRef
Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea
Yuri Cho, SeongBeom Park, SeonYoung Park, WonJung Choi, Book Kim, Helin Han
Infectious Diseases and Therapy.2023; 12(10): 2387.     CrossRef
Healthy Spouses can be Considered as Living Liver Donors
Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh
World Journal of Surgery.2022; 46(6): 1474.     CrossRef

15,998 View

173 Download

17 Web of Science

Crossref

Original Article

Liver Transplantation

Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea

Kyeong Deok Kim, Ji Eun Lee, Jong Man Kim, Okjoo Lee, Na Young Hwang, Jinsoo Rhu, Gyu-Seong Choi, Kyunga Kim, Jae-Won Joh

Clin Mol Hepatol 2021;27(4):603-615.
Published online September 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0137

Abstract

PDF
Supplementary Material

Background/Aims
Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo hepatitis B virus infection (DNH). We analyzed the long-term outcomes of a large cohort of liver transplantation (LT) patients receiving anti-HBc-positive grafts and evaluated the risk of DNH when hepatitis B immunoglobulin (HBIG) monotherapy was used as prophylaxis. We also compared the cost-effectiveness of HBIG and NAs.
Methods
We retrospectively reviewed 457 patients with anti-HBc-positive grafts and 898 patients with anti-HBc-negative grafts who underwent LT between January 2001 and December 2018. We compared recipient characteristics according to the anti-HBc status of the donor, and compared the costs of using NAs for the rest of the patient’s life and using HBIG to maintain hepatitis B surface antibody titers above 200 IU/L.
Results
The 1-, 5-, and 10-year patient survival rates were 87.7%, 73.5%, and 67.7%, respectively, in patients with anti-HBc-positive grafts, and 88.5%, 77.4%, and 70.3%, respectively, in patients with anti-HBc-negative grafts (P=0.113). Among 457 recipients with anti-HBc-positive grafts, 117 (25.6%) were non-HBV recipients. The overall incidence of DNH was 0.9%. When using HBIG under insurance coverage, the cumulative cost was lower compared with using NA continuously without insurance coverage in Korea.
Conclusions
Anti-HBc-positive grafts alone do not affect patient survival or graft survival. HBIG monoprophylaxis has good outcomes for preventing DNH, and the patient’s long-term cost burden is low in Korea because of the national insurance system in this cohort.

Citations

Citations to this article as recorded by

Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trap
Mauro Viganò, Roberta D’Ambrosio, Ciro Celsa, Agostino Colli, Nicola Coppola, Bruno Daniele, Elisabetta Degasperi, Gianpiero D’Offizi, Vito Di Marco, Stefano Fagiuoli, Martina Gambato, Corrado Girmenia, Paolo Grossi, Pietro Lampertico, Andrea Lauterio, Ma
Digestive and Liver Disease.2025; 57(12): 2257.     CrossRef
Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen
Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama
Diagnostics.2024; 14(7): 728.     CrossRef
Survival after liver transplantation from hepatitis B-core positive donors at a quaternary care hospital in Brazil
Fabiana Siroma, Edson Abdala, Stefanie Lima do Nascimento Castro, Wellington Andraus, Luiz Augusto Carneiro D´Álbuquerque, Alice Tung Wan Song
The Brazilian Journal of Infectious Diseases.2024; 28(6): 104384.     CrossRef
Long-term outcomes of active vaccination against de novo hepatitis B among pediatric recipients of living donor liver transplantations with anti-HBc (+) grafts: a retrospective case–control study
Chee-Chien Yong, Yu-Hung Lin, Wendell Z. Espinosa, I-Hsuan Chen, Shih-Ho Wang, Yi-Chia Chan, Chao-Long Chen, Chih-Che Lin
International Journal of Surgery.2024; 110(10): 6702.     CrossRef
Cost-effectiveness of Kidney Transplantation From Donors at Increased Risk of Blood-borne Virus Infection Transmission
Karan K. Shah, Melanie Wyld, James A. Hedley, Karen M.J. Waller, Nicole De La Mata, Angela C. Webster, Rachael L. Morton
Transplantation.2023; 107(9): 2028.     CrossRef

10,759 View

161 Download

6 Web of Science

Crossref

Review

Viral hepatitis

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol 2022;28(1):17-30.
Published online July 20, 2021

DOI: https://doi.org/10.3350/cmh.2021.0093

Abstract

PDF

Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the progression to cirrhosis and hepatocellular carcinoma, which are serious public health problems. Although universal vaccination programs exist, they are only prophylactic and not curative. In the HBV life cycle, HBV forms covalently closed circular DNA (cccDNA), which is the viral minichromosome, in the nuclei of human hepatocytes and makes it difficult to achieve a complete cure with the current nucleos(t)ide analogs and interferon therapies. Current antiviral therapies rarely eliminate cccDNA; therefore, lifelong antiviral treatment is necessary. Recent trials for antiviral treatment of chronic hepatitis B have been focused on establishing a functional cure, defined by either the loss of hepatitis B surface antigen, undetectable serum HBV DNA levels, and/or seroconversion to hepatitis B surface antibody. Novel therapeutic targets and molecules are in the pipeline for early clinical trials aiming to cure HBV infection. The ideal strategy for achieving a long-lasting functional or complete cure might be using combination therapies targeting different steps of the HBV life cycle and immunomodulators. This review summarizes the current knowledge about novel treatments and combination treatments for a complete HBV cure.

Citations

Citations to this article as recorded by

The Sustainable Goal of Eliminating Hepatitis B, Functional Cure, and the Prospect of NASVAC: A Review
Mamun Al Mahtab, Julio CA Rubido, Gerardo E Guillén, Eduardo Penton, Osamu Yoshida, Yoichi Hiasa, Sakirul Khan, Md Abdur Rahim, Noor-E-Alam Mohammad, Ahmed L Moben, Rokshana Begum, Musarrat Mahtab, Sheikh MF Akbar
Euroasian journal of hepato-gastroenterology.2026; 15(2): 178.     CrossRef
Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches
Prashant Tiwari, Istuti Saraswat, Jyoti Gupta
Current Microbiology.2026;[Epub]     CrossRef
Innate immune recognition and evasion strategies of hepatitis B virus: from DNA to RNA and viral proteins
Zhenghao Chen, Rui Hu, Huajun Ye, Qiuxun Chen, Yuhang Liu, Xinyu Zhang, Yingting Chen, You Wu, Ciliang Jin
Frontiers in Immunology.2026;[Epub]     CrossRef
Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor
Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren
Journal of Clinical Medicine.2026; 15(5): 1826.     CrossRef
Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers
Laura Iulia Bozomitu, Ancuta Lupu, Vasile Valeriu Lupu, Nicoleta Gimiga, Dana Teodora Anton Paduraru, Dana Elena Mîndru, Mihaela Mihai, Carmen Anton, Emil Anton, Mihaela Mitrea, Anca Adam-Raileanu, Lorenza Forna
International Journal of Molecular Sciences.2026; 27(5): 2464.     CrossRef
Predictive factors for clinical cure in the treatment of HBeAg(−) chronic hepatitis B or compensated cirrhosis: a prospective observational study
Yan-Qing Lv, Ru-Hua Guo, Kun-Yu Liu, Jia-Jie Li, Hui-Fan Ji
Frontiers in Medicine.2025;[Epub]     CrossRef
Cobalt Chloride–Mimicked Hepatocyte Cell Hypoxia Induces TREX1, Leading to Hepatitis B Virus Restriction
Rodolphe Suspène, Vincent Caval, Pierre Khalfi, Emmanuelle Pitré, Agnès Marchio, Pascal Pineau, Jean-Pierre Vartanian
The Journal of Infectious Diseases.2025; 231(6): 1559.     CrossRef
The sV184A Variant in HBsAg Specific to HBV Subgenotype C2 Leads to Enhanced Viral Replication and Apoptotic Cell Death Induced by PERK‐eIF2α‐CHOP‐Mediated ER Stress
Yu‐Min Choi, Dong Hyun Kim, Eun Ju Cho, Ziyun Kim, Junghwa Jang, Hyunsoo Kim, Su Jong Yu, Bum‐Joon Kim
Journal of Medical Virology.2025;[Epub]     CrossRef
Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B
Hae Lim Lee, Soon Kyu Lee, Ji Won Han, Hyun Yang, Heechul Nam, Pil Soo Sung, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
JHEP Reports.2025; 7(7): 101391.     CrossRef
Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry
Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim
Journal of Liver Cancer.2025; 25(1): 109.     CrossRef
Functional Cure for Hepatitis B Virus: Challenges and Achievements
Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein
International Journal of Molecular Sciences.2025; 26(8): 3633.     CrossRef
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis
Shun Li, Lichen Shi, Cheng Huang, Min Li, Tongtong Meng, Hao Wang, Xinyu Zhao, Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong
Annals of Hepatology.2025; 30(2): 101921.     CrossRef
A review of the progress and challenges of developing dendritic-based vaccines against hepatitis B virus (HBV)
Ali Ameri, Hossein Gandomkar, Hanan Hassan Ahmed, Radhwan Abdul Kareem, Hayder Naji Sameer, Ahmed Yaseen, Zainab H. Athab, Mohaned Adil, Iman Ghasemzadeh
Pathology - Research and Practice.2025; 271: 156025.     CrossRef
mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models
María José Limeres, Rocio Gambaro, Malin Svensson, Silvia Fraude-El Ghazi, Leah Pretsch, Daniel Frank, German A. Islan, Ignacio Rivero Berti, Matthias Bros, Ying K. Tam, Hiromi Muramatsu, Norbert Pardi, Stephan Gehring, Maximiliano L. Cacicedo
Molecular Therapy.2025; 33(9): 4156.     CrossRef
Novel Therapeutics for Hepatocellular Carcinoma
Mohamed I. Elsaid, Ashish Manne
Clinics in Liver Disease.2025; 29(4): 673.     CrossRef
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D
Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang
Virology Journal.2025;[Epub]     CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators
Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu
Drug Discovery Today.2025; 30(10): 104458.     CrossRef
Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review
Kaijie Yao, Hao Feng, Ying Chen, Yun Bao, Mengxia Yan, Wen Li, Bin Wu
Clinical Drug Investigation.2025; 45(10): 681.     CrossRef
Magnitude of Hepatitis B virus and associated factors among chronic liver disease patients admitted to the medical ward at Sheikh Hassen Yabare Comprehensive Specialized Hospital, Jigjiga, Ethiopia: a retrospective study
Ramadan Budul Yusuf, Getnet Addisu, Ahmed Mohammed Ibrahim, Terefe Gebre, Seid Muhumed Abdilaahi, Bilan Ali Ahmed, Abdulahi Hussen Abdinur, Girma Tadesse Wedajo, Mohamed Omar Osman, Tebelay Dilnessa
PLOS One.2025; 20(12): e0338702.     CrossRef
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies
Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang
World Journal of Gastroenterology.2024; 30(10): 1295.     CrossRef
Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now
Caecilia H C Sukowati, Sri Jayanti, Turyadi Turyadi, David H Muljono, Claudio Tiribelli
World Journal of Gastrointestinal Oncology.2024; 16(4): 1097.     CrossRef
N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H
Dimitrios Moianos, Maria Makri, Georgia-Myrto Prifti, Aristeidis Chiotellis, Alexandros Pappas, Molly E. Woodson, Razia Tajwar, John E. Tavis, Grigoris Zoidis
Molecules.2024; 29(12): 2942.     CrossRef
SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death
Jooyoung Lee, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Hye‐In An, Yong‐Jae Kwon, Hana Jin, Chan‐Gi Pack, Inki Kim, Young‐In Yoon, Gil‐Chun Park, Eun‐Kyoung Jwa, Jae Hyun Kwon, Jung‐Man Namgoong, Gi‐Won Song, Shin Hwang, Eunyoung Tak, Sung‐Gyu Lee
Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain
Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng
Viruses.2024; 16(7): 1151.     CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2024; 30(3): 539.     CrossRef
Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection
Kenneth Sherman, Susan Rouster, Heidi Meeds, Marion Peters, Jason Blackard, Paul Horn, Timothy Archampong, Awewura Kwara, Mark Anderson, Michael Stec, Gavin Cloherty
Pathogens and Immunity.2024; 9(2): 43.     CrossRef
Functional cure of chronic hepatitis B-hope or hype?
Gautam Ray
World Journal of Hepatology.2024; 16(9): 1199.     CrossRef
Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment
Xiaodi Li, Ling Xu, Lianfeng Lu, Xiaosheng Liu, Yang Yang, Yuanni Wu, Ting Zhu, Xiaoxia Li, Yanling Li, Xiaojing Song, Yang Han, Wei Lyu, Wei Cao, Taisheng Li
Journal of Translational Medicine.2024;[Epub]     CrossRef
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Cho-Rong Lee, Sung-Gyoo Park
Clinical and Molecular Hepatology.2024; 30(4): 724.     CrossRef
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Mehrangiz Dezhbord, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2024; 30(4): 1028.     CrossRef
A case report: cccDNA and pgRNA remain positive in liver tissue in a chronic hepatitis B patient with functional cure
Wenxiong Xu, Qiumin Luo, Yeqiong Zhang, Chan Xie, Liang Peng
Frontiers in Medicine.2024;[Epub]     CrossRef
Increased QPCT gene expression by the hepatitis B virus promotes HBV replication
Conghui Zhang, Qingfeng Ma, Wei Wang, Hui Song, Xue Wang, Fengxia Xu, Chengliang Zhu, Xinghui Liu, Seth Agyei Domfeh
PLOS ONE.2024; 19(11): e0312773.     CrossRef
Antiviral Therapy for Chronic Hepatitis B Infection Improves Outcomes After Total Hip Arthroplasty: A Multicenter Retrospective Study
Tao Cheng, Guoyong Li, Huiming Ning, Liang Hao
The Journal of Arthroplasty.2023; 38(2): 300.     CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 191.     CrossRef
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
Clinical and Molecular Hepatology.2023; 29(1): 113.     CrossRef
Overview of the development of HBV small molecule inhibitors
Huihui Yang, Weiwei Yao, Jinfei Yang
European Journal of Medicinal Chemistry.2023; 249: 115128.     CrossRef
The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang
Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice
Daisuke Ito, Hiroyasu Ito, Tatsuya Ando, Yasuhiro Sakai, Takayasu Ideta, Ken J. Ishii, Tetsuya Ishikawa, Masahito Shimizu
Hepatology Communications.2023;[Epub]     CrossRef
The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(2): 263.     CrossRef
The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 355.     CrossRef
Interactions of Na+/taurocholate cotransporting polypeptide with host cellular proteins upon hepatitis B and D virus infection: novel potential targets for antiviral therapy
Dariusz Zakrzewicz, Joachim Geyer
Biological Chemistry.2023; 404(7): 673.     CrossRef
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
BMC Gastroenterology.2023;[Epub]     CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
Beom Kyung Kim, Sang Hoon Ahn
Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Osamu Yoshida, Julio Aguilar, Guillen Nieto Gerardo, Yoichi Hiasa
Biomedicines.2023; 11(7): 1944.     CrossRef
Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies
Ankita Singh, Jitendra Kumar, Vijay Kumar
Current Topics in Medicinal Chemistry.2023; 23(18): 1727.     CrossRef
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA
An-Qi Zhuang, Yan Chen, Shan-Mei Chen, Wen-Cheng Liu, Yao Li, Wen-Jie Zhang, Yi-Hang Wu
Viruses.2023; 15(12): 2315.     CrossRef
Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery
Dariusz Zakrzewicz, Joachim Geyer
Biomedicines.2022; 10(1): 196.     CrossRef
Genotypes Variation and Molecular Epidemiology Of The Hbv Chronic Liver Infection In The Local Population Of Pakistan: An Overview Of The Recent Literature
Bushra Tahreem, Ghadir Ali, Haroon Ahmad, Asim Shahzad, Muhammad Khurram, Nabiha Naeem, Aquib Nazar, Muhammad Haris, Hassan ., Shahrukh .
Pakistan BioMedical Journal.2022;[Epub]     CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
Current Status of Drug Therapy for Chronic Hepatitis B
显明尹
Advances in Clinical Medicine.2022; 12(07): 6196.     CrossRef
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B
Chan‐Young Jung, Hyung Woo Kim, Jung Il Lee, Hyun Woong Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
Liver International.2022; 42(11): 2408.     CrossRef
Design, Synthesis and Evaluation of Novel 4‐(4‐Chlorobenzyl)‐6‐methylpyridazin‐3(2H)‐one Derivatives as Hepatitis B Virus Inhibitors
Oya Unsal Tan, Jan Moncol, David Durantel
ChemistrySelect.2022;[Epub]     CrossRef
Hepatitis B functional cure and immune response
Jia-Rui Zheng, Zi-Long Wang, Bo Feng
Frontiers in Immunology.2022;[Epub]     CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
Diagnostics.2022; 13(1): 3.     CrossRef
Critical Updates on Chronic Hepatitis B Virus Infection in 2021
Cyriac A Philips, Rizwan Ahamed, Jinsha K Abduljaleel, Sasidharan Rajesh, Philip Augustine
Cureus.2021;[Epub]     CrossRef

17,735 View

690 Download

58 Web of Science

Crossref

Editorial

Viral hepatitis

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol 2021;27(2):281-282.
Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

PDF

Citations

Citations to this article as recorded by

ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis
Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim
Clinical Gastroenterology and Hepatology.2023; 21(9): 2278.     CrossRef
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B
Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
Liver International.2023; 43(8): 1813.     CrossRef
Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient
Jong Chul Kim, Hye Young Lee, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Juhee Won, Soree Park, Na Yeon Kim, Jae Jin Shin, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo, Kyun-Hwan Kim
Biomedicines.2022; 10(2): 282.     CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Cancers.2021; 13(14): 3424.     CrossRef

7,387 View

104 Download

5 Web of Science

Crossref

First Prev

Page of 3

Next Last

Page Path

"Hepatitis B Virus"

Article category

Keywords

Publication year

Article category

Keywords

Publication Year

Funded articles

"Hepatitis B Virus"

Research Letters

Editorial

Correspondences

Review

Original Articles

Review

Correspondence

Research Letter

Editorial

Review

Letter to the Editor

Original Article

Reply to Correspondence

Editorials

Viral hepatitis

Reviews

Viral hepatitis

Viral hepatitis

Correspondence

Hepatic neoplasm

Reply to Correspondence

Hepatic neoplasm

Letter to the Editor

Viral hepatitis

Correspondence

Viral hepatitis

Reply to Correspondence

Viral hepatitis

Original Article

Viral hepatitis

Reply to Correspondence

Viral hepatitis

Editorial

Viral hepatitis

Original Article

Hepatic neoplasm

Editorials

Steatotic liver disease

Viral hepatitis

Original Articles

Viral hepatitis

Viral hepatitis

Viral hepatitis

Viral hepatitis

Review

Viral hepatitis

Editorial

Viral hepatitis

Review

Letter to the Editor

Viral hepatitis

Original Article

Viral hepatitis

Editorials

Viral hepatitis

Viral hepatitis

Original Article

Review

Snapshot

Viral hepatitis

Original Article

Liver Transplantation

Review

Viral hepatitis

Viral hepatitis

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS